EP2968246A1 - Omega-3 pentaenoic acid compositions and methods of use - Google Patents
Omega-3 pentaenoic acid compositions and methods of useInfo
- Publication number
- EP2968246A1 EP2968246A1 EP13878433.5A EP13878433A EP2968246A1 EP 2968246 A1 EP2968246 A1 EP 2968246A1 EP 13878433 A EP13878433 A EP 13878433A EP 2968246 A1 EP2968246 A1 EP 2968246A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alternatively
- dpa
- epa
- dha
- fatty acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 440
- 238000000034 method Methods 0.000 title claims abstract description 168
- YIYBQIKDCADOSF-UHFFFAOYSA-N pent-2-enoic acid Chemical compound CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 title description 5
- 239000000194 fatty acid Substances 0.000 claims abstract description 219
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 212
- 229930195729 fatty acid Natural products 0.000 claims abstract description 212
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 204
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 112
- 229940012843 omega-3 fatty acid Drugs 0.000 claims abstract description 97
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 19
- 208000019553 vascular disease Diseases 0.000 claims abstract description 17
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 16
- 208000024891 symptom Diseases 0.000 claims abstract description 16
- 230000003143 atherosclerotic effect Effects 0.000 claims abstract description 11
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 469
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims description 367
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims description 351
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 324
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 323
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 323
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 323
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 263
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 235
- 239000006014 omega-3 oil Substances 0.000 claims description 76
- 125000004494 ethyl ester group Chemical group 0.000 claims description 33
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 28
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 28
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 28
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 28
- 235000021588 free fatty acids Nutrition 0.000 claims description 27
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 24
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 24
- 210000004369 blood Anatomy 0.000 claims description 24
- 239000008280 blood Substances 0.000 claims description 24
- 150000002148 esters Chemical class 0.000 claims description 20
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims description 20
- 229940033080 omega-6 fatty acid Drugs 0.000 claims description 20
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 19
- 201000006370 kidney failure Diseases 0.000 claims description 19
- 208000010125 myocardial infarction Diseases 0.000 claims description 17
- 206010003119 arrhythmia Diseases 0.000 claims description 15
- 238000000502 dialysis Methods 0.000 claims description 15
- 208000030613 peripheral artery disease Diseases 0.000 claims description 14
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 13
- 201000001320 Atherosclerosis Diseases 0.000 claims description 10
- 208000017169 kidney disease Diseases 0.000 claims description 10
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 9
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 9
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 9
- 206010012289 Dementia Diseases 0.000 claims description 8
- 206010019280 Heart failures Diseases 0.000 claims description 8
- 235000009421 Myristica fragrans Nutrition 0.000 claims description 8
- 206010062237 Renal impairment Diseases 0.000 claims description 8
- 230000015271 coagulation Effects 0.000 claims description 8
- 238000005345 coagulation Methods 0.000 claims description 8
- 230000002259 coagulatory effect Effects 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 239000001115 mace Substances 0.000 claims description 8
- 208000028698 Cognitive impairment Diseases 0.000 claims description 7
- 208000000770 Non-ST Elevated Myocardial Infarction Diseases 0.000 claims description 7
- 208000017442 Retinal disease Diseases 0.000 claims description 7
- 206010038923 Retinopathy Diseases 0.000 claims description 7
- 208000010877 cognitive disease Diseases 0.000 claims description 7
- 238000011282 treatment Methods 0.000 abstract description 85
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract description 21
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 5
- 230000001258 dyslipidemic effect Effects 0.000 abstract description 2
- 230000002757 inflammatory effect Effects 0.000 abstract description 2
- 238000011321 prophylaxis Methods 0.000 abstract 1
- OQOCQFSPEWCSDO-JLNKQSITSA-N 6Z,9Z,12Z,15Z,18Z-Heneicosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O OQOCQFSPEWCSDO-JLNKQSITSA-N 0.000 description 178
- OQOCQFSPEWCSDO-UHFFFAOYSA-N heneicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCC(O)=O OQOCQFSPEWCSDO-UHFFFAOYSA-N 0.000 description 168
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 64
- MSHVEAAKYBMOTM-VVUKEZRKSA-N (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoic acid (6E,9E,12E,15E,18E)-henicosa-6,9,12,15,18-pentaenoic acid (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoic acid Chemical class CC/C=C/C/C=C/C/C=C/C/C=C/C/C=C/CCCCCC(=O)O.CC/C=C/C/C=C/C/C=C/C/C=C/C/C=C/CCCCC(=O)O.CC/C=C/C/C=C/C/C=C/C/C=C/C/C=C/CCCC(=O)O MSHVEAAKYBMOTM-VVUKEZRKSA-N 0.000 description 54
- 239000003921 oil Substances 0.000 description 41
- 235000019198 oils Nutrition 0.000 description 41
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 37
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 35
- 235000021342 arachidonic acid Nutrition 0.000 description 32
- 229940114079 arachidonic acid Drugs 0.000 description 32
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 28
- 239000000543 intermediate Substances 0.000 description 28
- 150000003626 triacylglycerols Chemical class 0.000 description 27
- 210000002966 serum Anatomy 0.000 description 26
- 108010028554 LDL Cholesterol Proteins 0.000 description 24
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 22
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000002775 capsule Substances 0.000 description 21
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 18
- 230000009467 reduction Effects 0.000 description 17
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- 210000002381 plasma Anatomy 0.000 description 16
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 15
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 15
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 15
- 239000012141 concentrate Substances 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 14
- 229960004488 linolenic acid Drugs 0.000 description 14
- 230000002792 vascular Effects 0.000 description 14
- 230000007211 cardiovascular event Effects 0.000 description 13
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 13
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 13
- 239000003963 antioxidant agent Substances 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 12
- 238000005538 encapsulation Methods 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000007903 gelatin capsule Substances 0.000 description 11
- 229960000984 tocofersolan Drugs 0.000 description 11
- -1 EPA and DPA Chemical class 0.000 description 10
- 108010023302 HDL Cholesterol Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- DTMGIJFHGGCSLO-FIAQIACWSA-N ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC.CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC DTMGIJFHGGCSLO-FIAQIACWSA-N 0.000 description 10
- 229940098330 gamma linoleic acid Drugs 0.000 description 10
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- KXVFBCSUGDNXQF-DZDBOGACSA-N (2z,4z,6z,8z,10z)-tetracosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C=C/C(O)=O KXVFBCSUGDNXQF-DZDBOGACSA-N 0.000 description 9
- 238000008214 LDL Cholesterol Methods 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000002285 corn oil Substances 0.000 description 9
- 235000005687 corn oil Nutrition 0.000 description 9
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 208000024172 Cardiovascular disease Diseases 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- 229940013317 fish oils Drugs 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000000250 revascularization Effects 0.000 description 6
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 5
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 229920001219 Polysorbate 40 Polymers 0.000 description 5
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 235000004626 essential fatty acids Nutrition 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 235000021323 fish oil Nutrition 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 229940115970 lovaza Drugs 0.000 description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 5
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 229940101027 polysorbate 40 Drugs 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 229940068965 polysorbates Drugs 0.000 description 5
- 229960002965 pravastatin Drugs 0.000 description 5
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229920001903 high density polyethylene Polymers 0.000 description 4
- 239000004700 high-density polyethylene Substances 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 235000004213 low-fat Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000006441 vascular event Effects 0.000 description 4
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 229960005110 cerivastatin Drugs 0.000 description 3
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 229960003765 fluvastatin Drugs 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- SZQQHKQCCBDXCG-BAHYSTIISA-N (2e,4e,6e)-hexadeca-2,4,6-trienoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C(O)=O SZQQHKQCCBDXCG-BAHYSTIISA-N 0.000 description 2
- HPSWUFMMLKGKDS-DNKOKRCQSA-N (2e,4e,6e,8e,10e,12e)-tetracosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O HPSWUFMMLKGKDS-DNKOKRCQSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 206010049993 Cardiac death Diseases 0.000 description 2
- 206010011906 Death Diseases 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 108010069201 VLDL Cholesterol Proteins 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229960004424 carbon dioxide Drugs 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000013066 combination product Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- PRHHYVQTPBEDFE-UHFFFAOYSA-N eicosatrienoic acid Natural products CCCCCC=CCC=CCCCCC=CCCCC(O)=O PRHHYVQTPBEDFE-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229960002600 icosapent ethyl Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 230000007358 intestinal barrier function Effects 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229960000672 rosuvastatin Drugs 0.000 description 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- XSXIVVZCUAHUJO-AVQMFFATSA-N (11e,14e)-icosa-11,14-dienoic acid Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCCC(O)=O XSXIVVZCUAHUJO-AVQMFFATSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102000018619 Apolipoproteins A Human genes 0.000 description 1
- 108010027004 Apolipoproteins A Proteins 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 1
- 229940097420 Diuretic Drugs 0.000 description 1
- 235000021297 Eicosadienoic acid Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000748159 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 35 Proteins 0.000 description 1
- 206010055171 Hypertensive nephropathy Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 238000012369 In process control Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010029158 Nephroptosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034498 Pericarditis uraemic Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- 206010038422 Renal cortical necrosis Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 201000003099 Renovascular Hypertension Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
- 102100040048 Ubiquitin carboxyl-terminal hydrolase 35 Human genes 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 229940049950 atorvastatin 10 mg Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 238000003965 capillary gas chromatography Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 229940105772 coagulation factor vii Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- VCSQUSNNIFZJAP-AAQCHOMXSA-N ethyl (7Z,10Z,13Z,16Z,19Z)-docosapentaenoate Chemical compound CCOC(=O)CCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC VCSQUSNNIFZJAP-AAQCHOMXSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940050507 fluvastatin 20 mg Drugs 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000010965 in-process control Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000002608 intravascular ultrasound Methods 0.000 description 1
- 238000005657 iodolactonization reaction Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000005430 kidney cortex necrosis Diseases 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 229940080791 lovastatin 10 mg Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000021288 n-6 DPA Nutrition 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940092966 pitavastatin 1 mg Drugs 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000006409 renal osteodystrophy Diseases 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000526 short-path distillation Methods 0.000 description 1
- 229940096805 simvastatin 5 mg Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to omega-3 fatty acid compositions, and methods of treating, preventing, reducing the occurrence of, and improving symptoms associated with coronary heart disease (CHD), vascular disease, atherosclerotic disease or related conditions.
- CHD coronary heart disease
- vascular disease vascular disease
- atherosclerotic disease or related conditions The present invention also provides methods for the treatment and/or prevention and/or reduction of cardiac events and/or cardiovascular events and/or vascular events and/or symptoms.
- Marine oils also commonly referred to as fish oils, are a good source of the two main omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which have been found to regulate lipid metabolism.
- Omega-3 fatty acids have been found to have beneficial effects on the risk factors for cardiovascular diseases, especially mild hypertension, hypertriglyceridemia and on the coagulation factor VII phospholipid complex activity.
- Omega-3 fatty acids lower serum triglycerides (TG), increase serum HDL-cholesterol, lower systolic and diastolic blood pressure and the pulse rate, and lower the activity of the blood coagulation factor Vll-phospholipid complex.
- omega-3 fatty acids seem to be well tolerated, without giving rise to any severe side effects.
- omega-3 fatty acids is a concentrate of omega-3, long chain, polyunsaturated fatty acids from fish oil containing DHA ethyl esters, EPA ethyl esters as well as ethyl esters of other omega-3 fatty acids (described in USP35 for LOVAZA®) and is sold under the trademarks OMACOR® and LOVAZA®.
- omega-3 fatty acid comprises at least 90% omega-3 fatty acids of which at least 80% EPA+DHA (in a ratio of 1.2:1 ) and is described, for example, in U.S. Pat. Nos... 5,502,077, 5,656,667 and 5,698,594.
- LOVAZA® (omega-3-acid ethyl esters) is indicated for the treatment of patients with hypertriglyceridemia with TG levels of 500mg/dL or higher.
- EPADEL® omega-3 fatty acid concentrate
- This product is described as 98% EPA ethyl ester in Lancet (Vol.369; March 31 , 2007; 1090-1098) reporting on a large outcome study with EPADEL®.
- EPADEL® is known to contain less than 1 % of any fatty acid other than EPA.
- omega-3 fatty acid concentrate also consists almost entirely of EPA ethyl ester and is known under its developmental stage name AMR101 or its trade name VASCEPA®.
- AMR101 is described in US patent application 2010/0278879 as comprising at least 95% EPA (typically referred to as 97% or at least 96% in company releases and references) and less than 1 % of any other fatty acid.
- AMR101 was previously under development for the treatment of Huntingdon's Disease but failed in phase III clinical development. Subsequently, AMR101 was entered in a development program for hypertriglyceridemia and mixed dyslipidemia.
- EPANOVATM omega-3, long chain, polyunsaturated fatty acids from fish oil containing approximately 75% DHA and EPA as free fatty acids. This product is described as comprising approximately 55% EPA and 20% DHA. EPANOVATM was previously under development for the treatment of Crohn's Disease but failed in phase III clinical development. Subsequently, EPANOVATM was entered in a development program for hypertriglyceridemia and mixed dyslipidemia.
- omega-3 fatty acid compositions are dose dependent, i.e., the higher the dose, the greater the therapeutic affect and bioavailability.
- the effect of each specific omega-3 fatty acid composition may be different, and therefore the level of therapeutic effect of one composition at a given dose cannot necessarily be inferred from the level of therapeutic effects of other omega-3 fatty acid compositions at the same or similar dose.
- Omega-3 fatty acids are known to be "essential fatty acids".
- EFAs essential fatty acids
- the main EFAs in the diet are linoleic acid of the omega-6 series and alpha-linolenic acid of the omega-3 series. However, to fulfill most of their biological effects these "parent" EFAs must be metabolised to the other longer chain fatty acids. Each fatty acid probably has a specific role in the body.
- n-6 series dihomo- gammalinolenic acid (DGLA, 20:3-n6) and arachidonic acid (ARA, 20:4-n6)
- DGLA dihomo- gammalinolenic acid
- ARA arachidonic acid
- EPA eicosapentaenoic acid
- DHA docosahexaenoic acid
- U.S. Patent No. 6,479,544 describes an invention in which it is found that ARA is highly desirable rather than undesirable and it may be helpful to administer ARA in association with EPA.
- This invention provides pharmaceutical formulations containing eicosapentaenoic acid or any appropriate derivative (hereinafter collectively referred to as EPA) and arachidonic acid (ARA), as set out in the granted claims for this patent.
- EPA eicosapentaenoic acid or any appropriate derivative
- ARA arachidonic acid
- ARA may be replaced by one or more of its precursors, DGLA or GLA.
- the ratio of EPA to ARA is preferably between 1 :1 and 20:1.
- Patent application PCT/GB 2004/000242 describes the treatment or prevention of psoriasis with a formulation comprising more than 95% EPA and less than 2% DHA.
- the EPA is replaced with DPA.
- Patent application PCT/NL 2006/050291 (WO/2007/058538, GB 0301701.9) describes combinations of idigestible oligosaccharides and long chain polyunsaturated fatty acids such as ARA, EPA, DA, and combinations thereof to improve intestinal barrier integrity, improving barrier function, stimulating gut maturation and/or reducing intestinal barrier permeability.
- Holub et al. discloses a study assessing the effect of oral supplementation with docosapentaenoic acid (DPA) on levels of serum and tissue lipid classes and their fatty acid compositions in rat liver, heart, and kidney.
- DPA docosapentaenoic acid
- Cardiovascular disease includes numerous problems, many of which are related to a process called atherosclerosis.
- Atherosclerosis is a condition that develops when plaque builds up in the walls of the arteries. This buildup narrows the arteries, making it harder for blood to flow through. If a blood clot forms, it can stop the blood flow. This can cause lead to conditions or event such as myocardial infarction, stroke, heart failure, arrhythmias, valve dysfunction, and death.
- the present invention provides omega-3 fatty acid compositions and methods of administering these compositions.
- the present invention provides a pharmaceutical composition
- fatty acids comprising omega-3 fatty acids, salts, esters, or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA) and wherein the ratio of docosahexaenoic acid to DHA to EPA (DHA:EPA) is less than 1 :10, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1.
- omega-3 fatty acids comprise eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA) and wherein the ratio of docosahexaenoic acid to DHA to EPA (DHA:EPA) is less than 1 :10, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1.
- EPA eicosapentaenoic acid
- DPA docos
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising eicosapentaenoic acid (EPA) in an amount between about 70% to about 95% of the total amount of fatty acids and docosapentaenoic acid (DPA) , wherein the composition comprises no more than 5% docosahexaenoic acid (DHA) of the total amount of fatty acids, and wherein the ratio of DHA: DPA is 1 :1 or lower.
- EPA eicosapentaenoic acid
- DPA docosapentaenoic acid
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising pharmaceutical composition comprising eicosapentaenoic acid (EPA) in an amount between about 750 mg/g to about 950 mg/g, and docosapentaenoic acid (DPA), wherein the composition comprises no more than 5% DHA of the total amount of fatty acids, and wherein the ratio of DHA: DPA is 1 :1 or lower.
- EPA eicosapentaenoic acid
- DPA docosapentaenoic acid
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising eicosapentaenoic acid (EPA) in a daily dosage amount of between about 1000 mg to about 5000 mg, and further comprising docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA), wherein the composition comprises no more than 5% DHA of the total amount of fatty acids, and wherein the ratio of DHA:DPA is 1 :1 or lower.
- EPA eicosapentaenoic acid
- DPA docosapentaenoic acid
- DHA docosahexaenoic acid
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA), wherein the amount of EPA and DPA is about 55% or more by weight of the total amount of fatty acids, and wherein the ratio of DHA:DPA is no more than 1 :1 .
- EPA eicosapentaenoic acid
- DPA docosapentaenoic acid
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising: docosapentaenoic acid (DPA) in an amount between about 50% to about 80% of the total amount of fatty acids, docosahexaenoic acid (DHA) in an amount between about 25% to about 40% of the total amount of fatty acids, and optionally eicosapentaenoic acid (EPA) in an amount less than about 10% of the total amount of fatty acids.
- DPA docosapentaenoic acid
- DHA docosahexaenoic acid
- EPA eicosapentaenoic acid
- compositions of the present invention comprise additional fatty acids, such as heneicosapentaenoic acid (HPA), arachidonic acid (ARA), and omega-6-docosapentaenoic acid (n-6 DPA), tetracosapentaenoic acid (TPA), and/or gamma-linoleic acid (GLA).
- HPA heneicosapentaenoic acid
- ARA arachidonic acid
- n-6 DPA omega-6-docosapentaenoic acid
- TPA tetracosapentaenoic acid
- GLA gamma-linoleic acid
- the present invention provides methods comprising administering the compositions.
- the present invention provides a method of treating, preventing, reducing the occurrence of, and improving symptoms associated with coronary heart disease (CHD), vascular disease, atherosclerotic disease or related conditions, comprising administering the compositions of the present invention to a subject in need thereof.
- the present invention also provides methods of treatment of patients by administering an effective amount of such compositions to a subject or a subject in need thereof, such as a subject prone to or afflicted with a vascular/cardiovascular disease or condition, a subject at risk of vascular/cardiovascular events, or a subject in need of treatment for a vascular/cardiovascular disease or condition.
- the present invention provides an orally administrable composition
- fatty acids wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts, esters, or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA) is less than 1 :20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 .
- omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the
- the present invention provides a pharmaceutical composition
- fatty acids comprising omega-3 fatty acids, salts, esters, or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA) and wherein the ratio of docosahexaenoic acid to DHA to EPA (DHA:EPA) is less than 1 :10, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 , and methods of using this composition.
- the composition comprises EPA in an amount between about 70% and about 95% of the total amount of fatty acids.
- the composition comprises less than about 5% of DHA of the total amount of fatty acids. In some embodiments, the composition comprises DPA in an amount of between about 5% and about 15% of the total amount of fatty acids. In some embodiments, the ratio of EPA to DPA (EPA:DPA) is less than about 1 :1 . In some embodiments, the composition further comprises heneicosapentaenoic acid (HPA) in an amount of at least 1 % of the total amount of fatty acids
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising eicosapentaenoic acid (EPA) in an amount between about 70% to about 95% of the total amount of fatty acids and docosapentaenoic acid (DPA), wherein the composition comprises no more than 5% docosahexaenoic acid (DHA) of the total amount of fatty acids, and wherein the ratio of DHA:DPA is 1 :1 or lower, and methods of using the composition.
- the composition comprises DPA in an amount of between about 5% and about 15% of the total amount of fatty acids.
- the composition further comprises heneicosapentaenoic acid (HPA) in an amount of at least 1 % of the total amount of fatty acids.
- HPA heneicosapentaenoic acid
- the ratio of EPA to DPA is less than about 1 :1. In some embodiments, the ratio of DHA:EPA is less than about 1 :10.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising pharmaceutical composition comprising eicosapentaenoic acid (EPA) in an amount between about 750 mg/g to about 950 mg/g, and docosapentaenoic acid (DPA), wherein the composition comprises no more than 5% DHA of the total amount of fatty acids, and wherein the ratio of DHA:DPA is 1 :1 or lower, and methods of using the composition.
- the composition comprises about 60 mg/g to about 120 mg/g of DPA.
- the ratio of DHA:EPA is less than 1 :10.
- the ratio of EPA:DPA is less than about 1 :1 .
- the composition further comprises heneicosapentaenoic acid (HPA) in an amount of at least 1 % of the total amount of fatty acids.
- HPA heneicosapentaenoic acid
- the present invention provides a pharmaceutical composition
- EPA eicosapentaenoic acid
- DPA docosapentaenoic acid
- DHA docosahexaenoic acid
- the composition comprises no more than 5% DHA of the total amount of fatty acids, and wherein the ratio of DHA:DPA is 1 :1 or lower, and methods of using the composition.
- the ratio of DHA:EPA is less than about 1 :10.
- the ratio of EPA:DPA is less than about 1 :1.
- the composition further comprises heneicosapentaenoic acid (HPA) in an amount of at least 1 % of the total amount of fatty acids.
- HPA heneicosapentaenoic acid
- the present invention provides a pharmaceutical composition
- EPA eicosapentaenoic acid
- DPA docosapentaenoic acid
- the composition comprises docosahexaenoic acid (DHA) in an amount of less than about 30% of the total amount of fatty acids.
- the composition comprises a daily dosage of DPA of greater than about 120 mg/day.
- the composition comprises omega-6 fatty acids in an amount of no more than 6% of total amount of fatty acids.
- the composition comprises DPA in an amount of at least 6% of the total amount of fatty acids.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising: docosapentaenoic acid (DPA) in an amount between about 50% to about 80% of the total amount of fatty acids, docosahexaenoic acid (DHA) in an amount between about 25% to about 40% of the total amount of fatty acids, and optionally eicosapentaenoic acid (EPA) in an amount less than about 10% of the total amount of fatty acids, and methods of using the composition.
- the composition comprises docosapentaenoic acid (DPA) in an amount between about 50% to 75%, alternatively about 50% to about 70%, alternatively about 50% to about 65%, or alternatively about 50% to about 60%, of the total amount of fatty acids.
- the composition comprises docosahexaenoic acid (DHA) in an amount between about 25% to about 38%, alternatively about 25% to about 35%, alternatively about 30% to about 35% of the total amount of fatty acids.
- the composition comprises eicosapentaenoic acid (EPA) in an amount less than about 9%, alternatively less than about 8%, alternatively less than about 7%, alternatively less than about 6%, alternatively less than about 5%, of the total amount of fatty acids.
- DHA docosahexaenoic acid
- EPA eicosapentaenoic acid
- the compositions of the present invention comprise at least 50% omega-3 fatty acids, alternatively at least 55%, alternatively at least 60%, alternatively at least 65%, alternatively at least 70%, alternatively at least 75%, alternatively at least 80%, alternatively at least 85%, alternatively at least 95%, most preferably at least 90% omega-3 fatty acids of the total amount of fatty acids.
- the composition comprises at least about 92% to about 99%, alteratively about 93% to about 98%, alternatively about 94% to about 98%, omega- 3 fatty acids of the total amount of fatty acids.
- EPA and DPA are jointly present in the compositions of the present invention at between about 55% and about 100% of total fatty acids, alternatively between about 60% and about 100%, alternatively between about 65% and about 100%, alternatively between about 70% and about 100%, alternatively between about 75% and about 100%, alternatively between about 80% and about 100%, alternatively between about 85% and about 95%, alternatively about 85% to about 100%, alternatively between about 85% and about 97%, alternatively between about 88% and about 95%, alternatively between about 88% and about 97%, alternatively about 88% to about 100%, alternatively between about 90% and about 95%, alternatively between about 90% and about 97%, alternatively about 90% to about 100%, alternatively about 95% to about 100%, alternatively about 97% to about 100% of the total amount of fatty acids.
- compositions of the present invention may be provided in a dose of between 100 mg and 10,100 mg/day, alternatively between 200 mg and 8,100 mg/day, alternatively between 300 mg and 6,100 mg/day, alternatively between 400 mg and 5,100 mg/day, alternatively between 500 mg and 4,100 mg/day.
- compositions and methods of the present invention may be provided in a dose of between 100 mg and 10,100 mg/day, alternatively between 200 mg and 8,100 mg/day, alternatively between 300 mg and 6,100 mg/day, alternatively between 400 mg and 5,100 mg/day, alternatively between 500 mg and 4,100 mg/day.
- the methods and compositions of the present invention may be provided in a dose of between 100 mg and 10,100 mg/day, alternatively between 200 mg and 8,100 mg/day, alternatively between 300 mg and 6,100 mg/day, alternatively between 400 mg and 5,100 mg/day, alternatively between 500 mg and 4,100 mg/day.
- the fatty acids such as EPA and DPA
- the fatty acids may be present in free fatty acid form, or as a salt, ester, or derivative.
- the fatty acids are preferably composed as a triglyceride, an ester (such as an ethyl ester) or free fatty acid.
- Other forms of the fatty acids which may be useful include salts, esters of any type, amides, mono-, di- or triglycerides, phospholipids or any other form which can lead to metabolization of the fatty acids (such as EPA and/or DPA), or the incorporation of the fatty acids (such as EPA and/or DPA) into body fluids, tissues or organs.
- Omega-3 fatty acids may be grouped by the number of double bonds contained in the fatty acid chain.
- HTA hexadecatrienoic acid
- alpha- linolenic acid (ALA) and eicosatrienoic acid (ETE) are omega-3-trienoic acids
- SDA stearidonic acid
- ETA eicosatetraenoic acid
- EPA heneicosapentaenoic acid
- DPA and tetracosapentaenoic acid TPA
- DHA and tetracosahexaenoic acid (THA) are omega-3-hexaenoic acids.
- omega-3- pentaenoic acids will refer to a mixture of at least two omega-3 pentaenoic acids in a ratio of at least 1 :25, more preferably in a ratio of at least 1 :50, more preferably in a ratio of at least 1 :75, more preferably in a ratio of at least 1 :100, more preferably in a ratio of at least 1 :125, more preferably in a ratio of at least :150, more preferably in a ratio of at least 1 :200.
- the ratio refers to the ratio of the least prevalent omega-3 pentaenoic acid in the mixture to the most prevalent omega- 3 pentaenoic acid in the mixture.
- compositions of the present invention comprise EPA, HPA, DPA and TPA, alternatively EPA and DPA, and alternatively the compositions of the present invention comprise EPA, HPA and DPA.
- the omega-3-pentaenoic acids in the compositions of the present invention comprise no more than 99.5% of a single omega-3-pentaenoic acid, alternatively no more than 99%; alternatively no more than 98.5%; alternatively no more than 98%; alternatively no more than 97.5%; alternatively no more than 96%; alternatively no more than 95%; alternatively no more than 94%; alternatively no more than 93%; alternatively no more than 92%; alternatively no more than 91 %; alternatively no more than 90%; alternatively no more than 88%; alternatively no more than 85%; alternatively no more than 80%; alternatively no more than 75%; alternatively no more than 70%; alternatively no more than 65%; alternatively no more than 60%; alternatively no more than 55%; alternatively no more than 50%; alternatively no more than 45%; alternatively no more than 40%; alternatively no more than 30%.
- compositions of the present invention wherein at least 10%, alternatively at least 20%, alternatively at least 25%, alternatively at least 35%, alternatively at least 50%, alternatively at least 60%, alternatively at least 65%, alternatively at least 70%, alternatively at least 75%, by weight of the fatty acids comprise omega-3-pentaenoic acids, salts, esters, or derivatives thereof.
- compositions and methods comprise significant amounts of omega-3-pentaenoic acids or their glycerol or ethyl esters may be used in the methods of the present invention.
- the compositions and methods comprise at least 100 mg omega-3-pentaenoic acids per day, alternatively at least 200mg omega-3-pentaenoic acids per day, alternatively at least 300mg omega-3-pentaenoic acids per day, alternatively at least 500mg omega-3- pentaenoic acids per day, alternatively at least 700mg omega-3-pentaenoic acids per day, alternatively at least 900mg omega-3-pentaenoic acids per day, alternatively at least 1000mg omega-3-pentaenoic acids per day, alternatively at least 1500mg omega-3-pentaenoic acids per day, alternatively at least 1900mg omega-3-pentaenoic acids per day, alternatively at least 2000mg omega-3- penta
- the compositions provide a DHA as compared to the amount of omega-3-pentaenoic acids (N3-5enoicFA) such that the DHA:N3- 5enoicFA ratio is no more than 15:1 of DHA:N3-5enoicFA, alternatively no more than 12:1 of DHA:N3-5enoicFA, alternatively no more than 10:1 of DHA:N3-5enoicFA, alternatively no more than 8:1 of DHA:N3-5enoicFA, alternatively no more than 5:1 of DHA:N3-5enoicFA, alternatively no more than 3:1 of DHA:N3-5enoicFA, alternatively no more than 2:1 of DHA:N3-5enoicFA, alternatively no more than 1 :1 of DHA:N3-5enoicFA, alternatively no more than 1 :2 of DHA:N3-5enoicFA, alternatively no more than 1 :3 of DHA:N3-5enoicFA, alternatively no more than 1 :5 of
- the compositions of the present invention comprise at least 0.01 % HPA of total fatty acids in the composition, alternatively at least 0.05% HPA, alternatively at least 0.10% HPA, alternatively at least 0.15% HPA, alternatively at least 0.2% HPA, alternatively at least 0.3% HPA, alternatively at least 0.4% HPA, alternatively at least 0.5% HPA, alternatively at least 0.75% HPA, alternatively at least 1 % HPA, alternatively at least 1.5% HPA, alternatively at least 2% HPA, alternatively at least 2.5% HPA, alternatively at least 3% HPA, alternatively at least 3.5% HPA, alternatively at least 4% HPA, alternatively at least 4.5% HPA, alternatively at least 5% HPA, alternatively at least 6% HPA, alternatively at least 7% HPA, alternatively the compositions of the present invention comprise at least 9% HPA of total fatty acids in the composition.
- the compositions of the present invention comprise no more than 20% HPA of total fatty acids in the composition, alternatively no more than 15% HPA, alternatively no more than 12% HPA, alternatively no more than 10% HPA, alternatively no more than 8% HPA, alternatively no more than 7% HPA, alternatively no more than 6% HPA, alternatively no more than 5% HPA, alternatively no more than 4% HPA, alternatively no more than 3% HPA, alternatively no more than 2% HPA, alternatively no more than 1.5% HPA, alternatively the compositions of the present invention comprise at least 1 % HPA of total fatty acids in the composition. In some embodiments, the compositions of the present invention comprise 1 % to 20% HPA of the total fatty acids in the composition.
- compositions of the present invention comprise about 1 % to about 6% HPA, alternatively about 2% to about 5% HPA, alternatively about 3% to about 4% HPA, relative to the total amount of fatty acids in the composition. In some embodiments, the compositions of the present invention comprise about 10 mg/g to about 50 mg/g HPA, alternatively about 15 mg/g to about 45 mg/g, alternatively about 20 mg/g to about 40 mg/g, alternatively about 25 mg/g to about 35 mg/g, alternatively about 30 mg/g HPA.
- the present invention provides compositions and methods which comprise significant amounts of omega-3 heneicosapentaenoic acid (HPA) or its glycerol or ethyl esters.
- the methods of treatment may provide to a subject in need thereof a dose of at least 10 mg HPA per day, alternatively at least 15 mg HPA per day, alternatively at least 20 mg HPA per day, alternatively at least 25 mg HPA per day, alternatively at least 30mg HPA per day, alternatively at least 40mg HPA per day, alternatively at least 50mg HPA per day, alternatively at least 60mg HPA per day, alternatively at least 70mg HPA per day, alternatively at least 80mg HPA per day, alternatively at least 90mg HPA per day, alternatively at least 100mg HPA per day, alternatively at least 120mg HPA per day, alternatively at least 150mg HPA per day, alternatively at least 160mg HPA per day, alternatively
- the compositions of the present invention comprise no more than 10% omega-3 fatty acids that are not omega-3-pentaenoic acids, alternatively no more than 9%, alternatively no more than 8%, alternatively no more than 7%, alternatively no more than 6%, alternatively no more than 5%, alternatively no more than 4.5%, alternatively no more than 4%, alternatively no more than 3.5%, alternatively no more than 3%, alternatively no more than 2.5%, alternatively no more than 2%, alternatively no more than 1.5%, alternatively no more than 1.25%, alternatively no more than 1 %, alternatively no more than 0.75%, alternatively no more than 0.5%, alternatively no more than 0.4%, alternatively no more than 0.3%, alternatively no more than 0.2%, alternatively the compositions of the present invention comprise no more than 0.1 % omega-3 fatty acids that are not omega-3- pentaenoic acids.
- the compositions comprise EPA and DPA in an EPA:DPA ratio between 99:1 and 1 :99 EPA:DPA, alternatively between 90:1 and 1 :90, alternatively between 60:1 and 1 :60, alternatively between 60:1 and 1 :20, alternatively between 60:1 and 1 :4, alternatively between 40:1 and 1 :20, alternatively between 30:1 and 1 :20, alternatively between 30:1 and 1 :10, alternatively between 30:1 and 1 :5, alternatively between 40:1 and 1 :4, alternatively between 30:1 and 1 :4, alternatively between 30:1 and 1 :2, alternatively between 30:1 and 1 :1 , alternatively between 30:1 and 2:1 , alternatively between 30:1 and 5:1 , alternatively between 20:1 and 1 :20, alternatively between 20:1 and 1 :10, alternatively between 20:1 and 1 :5, alternatively between 20:1 and 1 :2, alternatively
- the ratio of EPA:DPA is greater than 1 :1 , preferably greater than 2:1 , and more preferably greater than 5:1. In some embodiments, the ratio of EPA:DPA is 1 :1 to 25:1 , preferably 5:1 to 20:1 , more preferably 8:1 to 15:1 , even more preferably 9:1 to 13:1 , even more most preferably about 10:1 to 1 1 :1 , and most preferably about 10:1.
- the compositions comprise EPA in an amount between 55% and 95% relative to the total amount of fatty acids present in the composition, alternatively between 60% and 95%, alternatively between 65% and 95%, alternatively between 70% and 95%, alternatively between 75% and 95%, alternatively between 90% and 95%, alternatively between 80% and 95%, alternatively between 90% and 95%, alternatively between 55% and 90%, alternatively between 60% and 90%, alternatively between 65% and 90%, alternatively between 70% and 90%, alternatively between 75% and 90%, alternatively between 80% and 90%, alternatively between 85% and 90%, alternatively between 55% and 92%, alternatively between 60% and 92%, alternatively between 65% and 92%, alternatively between 70% and 92%, alternatively between 75% and 92%, alternatively between 80% and 92%, alternatively between 85% and 92%, alternatively between 55% and 93%, alternatively between 60% and 93%, alternatively between 65% and 93%, alternatively between 70% and 93%, alternatively between 75%
- compositions comprise about 70% to about 95%, 80% to about 90%, alternatively about 81 % to about 88%, alternatively about 82% to about 88%, alternatively about 83% to about 87%, alternatively about 84% to about 86%, alternatively about 85% EPA relative to the total amount of fatty acids present in the composition.
- the compositions comprise about 750 mg/g to about 950 mg/g, alternatively about 800 mg/g to about 900 mg/g, alternatively about 830 mg/g to about 870 mg/g, alternatively about 840 mg/g to about 870 mg/g, alternatively 845 mg/g to about 865 mg/g, alternatively 846 mg/g to about 860 mg/g, alternatively 847 mg/g to about 859 mg/g, alternatively about 848 mg/g to about 858 mg/g, alternatively about 849 mg/g to about 857 mg/g, alternatively about 850 mg/g to about 856 mg/g, alternatively about 851 mg/g to about 855 mg/g, alternatively about 852 mg/g to about 854 mg/g, alternatively about 853 mg/g EPA.
- compositions of the present invention are preferably provided in a dose of between 100 mg and 10,000 mg/day, alternatively between 200 mg and 8,000 mg/day, alternatively between 300 mg and 6,000 mg/day, alternatively between 400 mg and 5,000 mg/day, alternatively between 500 mg and 4,000 mg/day.
- compositions and methods of the present invention are provided in a dose of between about 1000 mg/day to about 5000 mg/day, alternatively about 1200 mg/day to about 3000 mg/day, alternatively about 1500 mg/day to about 2500 mg/day, alternatively 600 mg/day to about 1950 mg/day, alternatively about 1735 mg/day to about 1855 mg/day, alternatively about 1740 mg/day to about 1840 mg/day, alternatively about 1745 mg/day to about 1820 mg/day, alternatively about 1750 mg/day to about 1800 mg/day, alternatively about 1755 mg/day to about 1790 mg/day, alternatively about 1760 mg/day to about 1780 mg/day, alternatively about 1770 mg/day of EPA.
- the compostiions of the present invention are provided in a dose of between about 2300 mg/day to about 3000 mg/day, alternatively about 2400 mg/day to about 2800 mg/day, alternatively about 2520 mg/day to about 2780 mg/day, alternatively about 2600 mg/day to about 2700 mg/day, alternatively about 2610 mg/day to about 2680 mg/day, alternatively about 2620 mg/day to about 2670 mg/day, alternatively about 2630 mg/day to about 2665 mg/day, alternatively about 2640 mg/day to about 2660 mg/day, alternatively about 2650 mg/day of EPA.
- the compostions of the present invention are provided in a dose of between about 3200 mg/day to about 3900 mg/day, alternatively 3300 mg/day to about 3800 mg/day, alternatively 3360 mg/day to about 3710 mg/day, alternatively about 3400 mg/day to about 3700 mg/day, alternatively about 3450 mg/day to about 3650 mg/day, alternatively about 3500 mg/day to about 3600 mg/day, alternatively about 3530 mg/day to about 3580 mg/day, alternatively about 3540 mg/day to about 3560 mg/day, alternatively about 3550 mg/day of EPA.
- compositions of the present invention are provided in a dose of between about about 1650 mg/day to about 2050 mg/day, alternatively about 1700 mg/day to about 2000 mg/day, alternatively about 1750 mg/day to about 1950 mg/day, alternatively about 1775 mg/day to about 1925 mg/day, alternatively about 1800 mg/day to about 1900 mg/day, alternatively about 1800 mg/day to about 2000 mg/day, alternatively about 1820 mg/day to about 1880 mg/day, alternatively about 1830 mg/day to about 1870 mg/day, alternatively about 1840 mg/day to about 1860 mg/day, alternatively about 1850 mg/day of EPA.
- the compostions of the present invention are provided in a dose of between about about 2500 mg/day to about 3100 mg/day, alternatively about 2600 mg/day to about 2000 mg/day, alternatively about 2650 mg/day to about 2950 mg/day, alternatively about 2700 mg/day to about 2900 mg/day, alternatively about 2725 mg/day to about 2875 mg/day, alternatively about 2750 mg/day to about 2850 mg/day, alternatively about 2780 mg/day to about 2820 mg/day, alternatively about 2790 mg/day to about 2810 mg/day, alternatively about 2800 mg/day of EPA.
- the compostions of the present invention are provided in a dose of between about 3300 mg/day to about 4000 mg/day, alternatively about 3400 mg/day to about 3900 mg/day, alternatively about 3500 mg/day to about 3900 mg/day, alternatively about 3550 mg/day to about 3850 mg/day, alternatively about 3600 mg/day to about 3800 mg/day, alternatively about 3650 mg/day to about 3750 mg/day, alternatively about 3680 mg/day to about 3725 mg/day, alternatively about 3690 mg/day to about 3710 mg/day, alternatively about 3700 mg/day of EPA.
- compositions of the present invention are provided in a dose of between about 1500 mg/day to about 2500 mg/day, alternatively about 1750 mg/day to about 2300 mg/day, alternatively about 1800 mg/day to about 2200 mg/day, alternatively about 1900 mg/day to about 2100 mg/day, alternatively about 1950 mg/day to about 2050 mg/day, alternatively about 1975 mg/day to about 2025 mg/day, alternatively about 2000 mg/day of EPA.
- compositions of the present invention are provided in a dose of between about 2500 mg/day to about 3500 mg/day, alternatively about 2700 mg/day to about 3300 mg/day alternatively about 2750 mg/day to about 3300 mg/day, alternatively about 2800 mg/day to about 3200 mg/day, alternatively about 2900 mg/day to about 3100 mg/day, alternatively about 2950 mg/day to about 3050 mg/day, alternatively about 2975 mg/day to about 3025 mg/day, alternatively about 3000 mg/day of EPA.
- compositions of the present invention are provided in a dose of between about 3500 mg/day to about 4500 mg/day, alternatively about 3700 mg/day to about 4300 mg/day, alternatively about 3750 mg/day to about 4300 mg/day, alternatively about 3800 mg/day to about 4200 mg/day, alternatively about 3900 mg/day to about 4100 mg/day, alternatively about 3950 mg/day to about 4050 mg/day, alternatively about 3975 mg/day to about 4025 mg/day, alternatively about 4000 mg/day of EPA.
- the compositions comprise DPA in an amount between 1 % and 99% relative to the total amount of fatty acids present in the composition, alternatively between 1 % and 95%, alternatively alternativelybetween 1 % and 90%, alternatively between 1 % and 85%, alternatively between 1 % and 80%, alternatively between 1 % and 75%, alternatively between 1 % and 70%, alternatively between 1 % and 65%, alternatively between 1 % and 60%, alternatively between 1 % and 55%, alternatively between 1 % and 50%, alternatively between 1 % and 45%, alternatively between 1 % and 40%, alternatively between 1 % and 35%, alternatively between 1 % and 30%, alternatively between 1 % and 25%, alternatively between 1 % and 20%, alternatively between 1 % and 15%, alternatively between 1 % and 10%, alternatively between 1 % and 5%, alternatively between 2% and 99%, alternatively between 2% and 95%, alternatively between 2% and 90%, alternatively between alternatively between 2% and 95%, alternatively between
- compositions comprise docosapentaenoic acid (DPA) in an amount between about 5% to about 15%, alternatively about 6% to about 12%, alternatively about 7% to about 1 1 %, alternatively about 8% to about 10% relative to the total amount of fatty acids present in the composition.
- DPA docosapentaenoic acid
- the composition comprises at least about 4% or at least about 5% or at least about 6% or at least about 7% or at least about 8% or at least about 9% or at least about 10% or at least about 15% or at least about 20% or at least about 25% or at least about 30% or at least about 35% or at least about 40% or at least about 45% or at least about 50% or at least about 55% or at least about 60% or at least about 65% or at least about 70% or at least about 75% or at least about 80% or at least about 85% or at least about 90% or at least about 95% of docosapentaenoic acid (DPA).
- DPA docosapentaenoic acid
- compositions comprise docosapentaenoic acid (DPA) in an amount of about 60 mg/g to about 120 mg/g, alternatively about 70 mg/g to about 100 mg/g, 75 mg/g to about 90 mg/g, alternatively about 77 mg/g to about 85 mg/g, alternatively about 78 mg/g to about 84 mg/g, alternatively about 79 mg/g to about 83 mg/g, alternatively about 80 mg/g to about 82 mg/g, alternatively about 81 mg/g to about 82 mg/g.
- DPA docosapentaenoic acid
- compositions comprise docosapentaenoic acid (DPA) in an daily dosage amount of at least about 20 mg/day, alternatively at least about 25 mg/day, alternatively at least about 30 mg/day, alternatively at least about 40 mg/day, alternatively at least about 50 mg/day, alternatively at least about 60 mg/day alternatively, at least about 70 mg/day alternatively at least about 75 mg/day, alternatively at least about 80 mg/day, alternatively at least about 90 mg/day, alternatively at least about 100 mg/day, alternatively at least about 120 mg/day, alternatively at least about 150 mg/day, alternatively at least about 160 mg/day, alternatively at least about 180 mg/day, alternatively at least about 200 mg/day, alternatively at least about 250 mg/day, alternatively at least about 300 mg/day, alternatively at least about 350 mg/day, or alternatively at least about 400 mg/day, alternatively at least about 500 mg/day, alternatively at least about 600 mg/day, alternatively at least about 800 mg
- DPA do
- the composition comprises DPA in a daily dosage of about 120 mg/day to about 150 mg/day, alternatively about 150 mg/day to about 200 mg/day, alternatively about 200 mg/day to about 250 mg/day, alternatively about 250 mg/day to about 300 mg/day, alternatively about 300 mg/day to about 400 mg/day, alternatively about 400 mg/day to about 600 mg/day, alternatively about 600 mg/day to about 1000 mg/day.
- the method of treatment provides a dose of at least about 1 mg/kg of docosapentaenoic acid (DPA) per day, alternatively about 2 mg/kg of DPA per day, alternatively about 3 mg/kg of DPA per day, alternatively about 4 mg/kg of DPA per day, alternatively about 6 mg/kg of DPA per day, alternatively about 8 mg/kg of DPA per day, alternatively about 10 mg/kg of DPA per day, alternatively about 20 mg/kg of DPA per day, alternatively about 30 mg/kg of DPA per day, and alternatively about 40 mg/kg of DPA per day, alternatively about 50 mg/kg of DPA per day, alternatively about 75 mg/kg of DPA per day, and alternatively about 100 mg/kg of DPA per day.
- DPA docosapentaenoic acid
- a relatively small amount of docosahexaenoic acid (DHA) as compared to EPA is present.
- the compositions of the present invention comprise no more than 1 :1 of DHA:EPA, alternatively no more than 1 :2, alternatively no more than 1 :3, alternatively no more than 1 :3, alternatively no more than 1 :4, alternatively no more than 1 :5 of DHA:EPA, alternatively no more than 1 :6 of DHA:EPA, alternatively no more than 1 :7 of DHA:EPA, alternatively no more than 1 :8 of DHA:EPA, alternatively no more than 1 :9 of DHA:EPA, alternatively no more than 1 :10 of DHA:EPA, alternatively no more than 1 :12 of DHA:EPA, alternatively no more than 1 :15 of DHA:EPA, alternatively no more than 1 :20 of DHA:EPA, alternatively no more than 1 :25 of DHA:EPA, alternatively no more
- DHA may be present in the compositions of this invention at a relative amount of ratio less than 1 % than the amount of EPA.
- DHA docosahexaenoic acid
- DHA may be present in the compositions of this invention at a DHA:EPA ratio of less than 1 :99.
- a relatively small amount of docosahexaenoic acid (DHA) relative to the total amount of fatty acids present in the composition is present.
- the compositions of the present invention comprise no more than 30% DHA, alternatively no more than 20% DHA, alternatively no more than 15% DHA, alternatively no more than 12% DHA, alternatively no more than 10% DHA, alternatively no more than 9% DHA, alternatively no more than 8% DHA, alternatively no more than 7% DHA, alternatively no more than 6% DHA, alternatively no more than 5% DHA, alternatively no more than 4% DHA, alternatively no more than 3% DHA, alternatively no more than 2% DHA, alternatively no more than 1 % DHA relative to the total amount of fatty acids present in the composition.
- compositions and methods comprise less than 1500mg of DHA, alternatively less than 1200mg of DHA, alternatively less than 1000mg of DHA, alternatively less than 800mg of DHA, alternatively less than 700mg of DHA, alternatively less than 600mg of DHA, alternatively less than 500mg of DHA, alternatively less than 400mg of DHA, alternatively less than 350mg of DHA, alternatively less than 300mg of DHA, alternatively less than 250mg of DHA, alternatively less than 200mg of DHA alternatively less than 150mg of DHA, alternatively less than 120mg of DHA, alternatively less than 100 mg of DHA, alternatively less than 80 mg of DHA, alternatively less than 60 mg of DHA, alternatively less than 40 mg of DHA, alternatively less than 30 mg of DHA, alternatively less than 25 mg of DHA, alternatively less than 20 mg of DHA or its glycerol or ethyl esters as a totally daily dose.
- the composition comprises about 5 mg/g to about 20 mg/g, alternatively about 8 mg/g to about 18 mg/g, alternatively about 9 mg/g to about 15 mg/g, alternatively about 10 mg/g to about 14 mg/g, alternatively about 1 1 mg/g to about 13 mg/g, alternatively about 12 mg/g to about 13 mg/g of docosahexaenoic acid (DHA).
- DHA docosahexaenoic acid
- the ratio of EPA:HPA is about 1500:1 to 25:1 , alternatively 1000:1 to 50:1 , alternatively 800:1 to 60:1 , alternatively 500:1 to 60:1 , alternatively 250:1 to 75:1 , and alternatively 100:1 to 80:1. In some preferred embodiments, the ratio of EPA:HPA is about 85:1. In some preferred embodiments, the ratio of EPA:HPA is about 30:1 .
- the ratio of DPA:HPA is about 250:1 to 1 :1 , alternatively 200:1 to 2:1 , alternatively 150:1 to 3:1 , alternatively 100:1 to 4:1 , alternatively 50:1 to 5:1 , alternatively 25:1 to 6:1 , and alternatively 10:1 to 7:1. In some preferred embodiments, the ratio of DPA:HPA is about 8:1. In some embodiments, the ratio of DPA:HPA is about 3:0.
- compositions of the present invention comprise no more than 15:1 of DHA:DPA, alternatively no more than 12:1 of DHA:DPA, alternatively no more than 10:1 of DHA:DPA, alternatively no more than 8:1 of DHA:DPA, alternatively no more than 5:1 of DHA:DPA, alternatively no more than 4:1 of DHA:DPA, alternatively no more than 3:1 of DHA:DPA, alternatively no more than 2:1 of DHA:DPA, alternatively no more than 1 :1 of DHA:DPA, alternatively no more than 1 :2 of DHA:DPA, alternatively no more than 1 :3 of DHA:DPA, alternatively no more than 1 :4 of DHA:DPA, alternatively no more than 1 :5 of DHA:DPA, alternatively no more than 1 :6 of DHA:DPA, alternatively no more than 1 :
- compositions of the present invention comprise no more than 15:1 of DHA:HPA, alternatively no more than 12:1 of DHA:HPA, alternatively no more than 10:1 of DHA:HPA, alternatively no more than 8:1 of DHA:HPA, alternatively no more than 5:1 of DHA:HPA, alternatively no more than 3:1 of DHA:HPA, alternatively no more than 2:1 of DHA:HPA, alternatively no more than 1 :1 of DHA:HPA, alternatively no more than 1 :2 of DHA:HPA, alternatively no more than 1 :3 of DHA:HPA, alternatively no more than 1 :5 of DHA:HPA, alternatively no more than 1 :8 of DHA:HPA, alternatively no more than 1 :10 of DHA:HPA, alternatively no more than 1 :15 of DHA:HPA, alternatively no more than
- compositions of the present invention comprise no more than 10% omega-6 fatty acids relative to the total amount of fatty acids, alternatively no more than 9%, alternatively no more than 8%, alternatively no more than 7%, alternatively no more than 6%, alternatively no more than 5%, alternatively no more than 4.5%, alternatively no more than 4%, alternatively no more than 3.5%, alternatively no more than 3%, alternatively no more than 2.5%, alternatively no more than 2%, alternatively no more than 1.7%, alternatively no more than 1.5%, alternatively no more than 1.2%, alternatively no more than 1 %, alternatively no more than 0.5% omega-6 fatty acids versus the total amount of fatty acids comprised by the compositions of the present invention.
- Omega-6 fatty acids include, but are not limited to: linoleic acid (LA; C18:2- n6); gamma-linoleic acid (GLA; C18:3-n6); eicosadienoic acid (C20:2-n6); dihomo- gamma-linoleic acid (DGLA; C20:3-n6); arachiconic acid (ARA; C20:4-n6); and omega-6 docosapentaenoic acid (DPA; C22:5-n6).
- LA linoleic acid
- GLA gamma-linoleic acid
- C20:2-n6 eicosadienoic acid
- DGLA dihomo- gamma-linoleic acid
- ARA arachiconic acid
- DPA omega-6 docosapentaenoic acid
- compositions of the present invention comprise no more than 10% omega-6 fatty acids relative to the total amount of omega-3 fatty acids plus omega-6 fatty acids, alternatively no more than 9%, alternatively no more than 8%, alternatively no more than 7%, alternatively no more than 6%, alternatively no more than 5%, alternatively no more than 4.5%, alternatively no more than 4%, alternatively no more than 3.5%, alternatively no more than 3%, alternatively no more than 2.5%, alternatively no more than 2%, alternatively no more than 1 .7%, alternatively no more than 1 .5%, alternatively no more than 1.2%, alternatively no more than 1 %, alternatively no more than 0.5% omega-6 fatty acids versus the total amount of omega-3 fatty acids plus omega-6 fatty acids comprised by the compositions of the present invention.
- compositions of the present invention comprise no more than 8% arachidonic acid (ARA; C20:4-n6) relative to the total amount of omega-3 fatty acids plus omega-6 fatty acids, alternatively no more than 7%, alternatively no more than 6%, alternatively no more than 5%, alternatively no more than 4.5%, alternatively no more than 4%, alternatively no more than 3.5%, alternatively no more than 3%, alternatively no more than 2.5%, alternatively no more than 2%, alternatively no more than 1.7%, alternatively no more than 1.5%, alternatively no more than 1 .2%, alternatively no more than 1 %, alternatively no more than 0.5% arachidonic acid (ARA; C20:4-n6) versus the total amount of omega-3 fatty acids plus omega-6 fatty acids comprised by the compositions of the present invention.
- ARA arachidonic acid
- a relatively small amount of omega-3 fatty acids in aggregate other than EPA, ETA, HPA and DPA (alternatively indicated as non-EPA, non-ETA, non-HPA and non-DPA omega-3 fatty acids in aggregate) relative to the total amount of fatty acids present in the composition is present.
- compositions of the present invention comprise no more than 20% non-EPA, non-ETA, non-HPA and non-DPA omega-3 fatty acids, alternatively no more than 15% non-EPA, non-ETA, non-HPA and non-DPA omega-3 fatty acids, alternatively no more than 12% non-EPA, non-ETA, non-HPA and non-DPA omega- 3 fatty acids, alternatively no more than 10% non-EPA, non-ETA, non-HPA and non- DPA omega-3 fatty acids, alternatively no more than 8% non-EPA, non-ETA, non- HPA and non-DPA omega-3 fatty acids, alternatively no more than 7% non-EPA, non-ETA, non-HPA and non-DPA omega-3 fatty acids, alternatively no more than 6% non-EPA, non-ETA, non-HPA and non-DPA omega-3 fatty acids, alternatively no more than 5% non-EPA, non-ETA, non-HPA and non-DPA omega-3 fatty acids, alternatively no more than 5% non-EPA,
- a relatively small amount of the sum of ALA, SDA and DHA relative to the total amount of fatty acids present in the composition is present, while at the same time large amounts of the sum of EPA, DPA-n3, HPA and ETA are present.
- compositions of the present invention comprise no more than 20% of the sum of ALA, SDA and DHA, alternatively no more than 15% of the sum of ALA, SDA and DHA, alternatively no more than 12% of the sum of ALA, SDA and DHA, alternatively no more than 10% of the sum of ALA, SDA and DHA, alternatively no more than 8% of the sum of ALA, SDA and DHA, alternatively no more than 7% of the sum of ALA, SDA and DHA, alternatively no more than 6% of the sum of ALA, SDA and DHA, alternatively no more than 5% of the sum of ALA, SDA and DHA, alternatively no more than 4% of the sum of ALA, SDA and DHA, alternatively no more than 3% of the sum of ALA, SDA and DHA, alternatively no more than 2% of the sum of ALA, SDA and DHA, alternatively no more than 1 % of the sum of ALA, SDA and DHA relative to the total amount of
- compositions of the present invention comprise no more than 8% arachidonic acid (ARA; C20:4-n6) relative to the total amount of fatty acids, alternatively no more than 7%, alternatively no more than 6%, alternatively no more than 5%, alternatively no more than 4.5%, alternatively no more than 4%, alternatively no more than 3.5%, alternatively no more than 3%, alternatively no more than 2.5%, alternatively no more than 2%, alternatively no more than 1.7%, alternatively no more than 1 .5%, alternatively no more than 1 .2%, alternatively no more than 1 %, alternatively no more than 0.5% arachidonic acid (ARA; C20:4-n6) relative the total amount of fatty acids comprised by the compositions of the present invention.
- ARA arachidonic acid
- compositions of the present invention comprise no more than 2.5% arachidonic acid (ARA; C20:4-n6), no more than 0.4% omega-6- docosapentaenoic acid (DPA; C22:5-n6) and no more than 0.2% gamma-linoleic acid (GLA; C18:3-n6) relative the total amount of fatty acids comprised by the compositions of the present invention.
- ARA arachidonic acid
- DPA omega-6- docosapentaenoic acid
- GLA gamma-linoleic acid
- fatty acid compositions comprising no more than 2.5% arachidonic acid (ARA; C20:4-n6), no more than 0.3% omega-6 docosapentaenoic acid (DPA; C22:5-n6) and no more than 0.1 % gamma-linoleic acid (GLA; C18:3-n6) relative the total amount of fatty acids comprised by the compositions of the present invention.
- ARA arachidonic acid
- DPA docosapentaenoic acid
- GLA gamma-linoleic acid
- the composition of the present invention further comprises TPA at concentration of at least 0.05%.
- the TPA concentration is about 0.01 % to about 5%, alternatively about 0.05% to about 2%, alternatively about 0.1 % to about 1 %, alternatively about 0.2% to about 0.8%, alternatively about 0.4% to about 0.6%, alternatively about 0.5%.
- compositions of the present invention may also be taken as a general nutritional supplement.
- the active ingredient of the formulations of the present invention consists essentially wholly of the EPA and DPA or precursors thereof (ethyl ester, triglyceride, or any other pharmaceutically acceptable salt or derivative thereof).
- no large amounts preferably less than 15%, alternatively less than 12%, alternatively less than 10%, alternatively less than 9%, alternatively less than 8%, alternatively less than 7%, alternatively less than 6%, alternatively less than 5%, alternatively less than 4%, alternatively less than 3%, alternatively less than 2%, alternatively less than 1 %, alternatively less than 0.5%, alternatively less than 0.25%
- any other fatty acids are present.
- the active ingredient of the formulations of the present invention consists essentially wholly of omega-3-pentaenoic acids or precursors thereof (ethyl ester, triglyceride, or any other pharmaceutically acceptable salt or derivative thereof).
- no large amounts preferably less than 15%, alternatively less than 12%, alternatively less than 10%, alternatively less than 9%, alternatively less than 4%, alternatively less than 4%, alternatively less than 4%, alternatively less than 4%, alternatively less than 4%, alternatively less than 4%, alternatively less than 4%, alternatively less than 3%, alternatively less than 2%, alternatively less than 1 %, alternatively less than 0.5%, alternatively less than 0.25%
- any other fatty acids are present.
- the fatty acid percentage is determined on a weight/weight, mol/mol, or chromatography area percent basis relative to all fatty acids present in the composition as determined by methods such as disclosed in the European Pharmacopeia monograph for omega-3 fatty acid concentrates, European Pharmacopeia monograph for omega-3-acid ethyl esters 90%, or European Pharmacopeia monograph method 2.4.29, USP monograph for fish oil dietary supplements, USP 35 omega-3-acid ethyl esters (LOVAZA®) monograph, or any essentially equivalent methods (whether by gas chromatography, HPLC, FPLC or any other chromatographic method).
- the fatty acid percentage is determined not as a percentage of all fatty acids present in the composition but as a specific type of fatty acid ethyl esters as percentage of all fatty acid ethyl esters present in the composition, thus excluding from the fatty acid percentage determination such fatty acids present as, for instance: free fatty acids; mono-, di-, and tri-glycerides; or fatty acids present in phospholipids (such as phosphatidylserine or phosphatidylcholine) or polysorbates (such as Tween 80, Tween 20, or polysorbate 40).
- phospholipids such as phosphatidylserine or phosphatidylcholine
- polysorbates such as Tween 80, Tween 20, or polysorbate 40.
- the fatty acid percentage is determined not as a percentage of all fatty acids present in the composition but as a specific type of free fatty acid as percentage of all free fatty acids present in the composition, thus excluding from the fatty acid percentage determination such fatty acids present as, for instance: fatty acid ethyl esters; mono-, di-, and tri-glycerides; or fatty acids present in phospholipids (such as phosphatidylserine or phosphatidylcholine) or polysorbates (such as Tween 80, Tween 20, or polysorbate 40).
- fatty acids present for instance: fatty acid ethyl esters; mono-, di-, and tri-glycerides; or fatty acids present in phospholipids (such as phosphatidylserine or phosphatidylcholine) or polysorbates (such as Tween 80, Tween 20, or polysorbate 40).
- the fatty acid percentage is determined not as a percentage of all fatty acids present in the composition but as a specific type of glycerol fatty acid ester as percentage of all glycerol fatty acid esters present in the composition, thus excluding from the fatty acid percentage determination such fatty acids present as, for instance: fatty acid ethyl esters; free fatty acids; or fatty acids present in phospholipids (such as phosphatidylserine or phosphatidylcholine) or polysorbates (such as Tween 80, Tween 20, or polysorbate 40).
- fatty acids present for instance: fatty acid ethyl esters; free fatty acids; or fatty acids present in phospholipids (such as phosphatidylserine or phosphatidylcholine) or polysorbates (such as Tween 80, Tween 20, or polysorbate 40).
- the fatty acid percentage is determined not as a percentage of all fatty acids present in the composition but as di- or tri-fatty acid esters with glycerol as percentage of all glycerol di- and tri-fatty acid esters present in the composition, thus excluding from the fatty acid percentage determination such fatty acids present as, for instance: glycerol-mono-fatty acid esters; fatty acid ethyl esters; free fatty acids; or fatty acids present in phospholipids (such as phosphatidylserine or phosphatidylcholine) or polysorbates (such as Tween 80, Tween 20, or polysorbate 40).
- phospholipids such as phosphatidylserine or phosphatidylcholine
- polysorbates such as Tween 80, Tween 20, or polysorbate 40.
- the fatty acid percentage is determined not as a percentage of all fatty acids present in the composition but as a tri-fatty acid esters with glycerol as percentage of all glycerol tri-fatty acid esters present in the composition, thus excluding from the fatty acid percentage determination such fatty acids present as, for instance: mono- and di-fatty acid esters of glycerol; fatty acid ethyl esters; free fatty acids; or fatty acids present in phospholipids (such as phosphatidylserine or phosphatidylcholine) or polysorbates (such as Tween 80, Tween 20, or polysorbate 40).
- phospholipids such as phosphatidylserine or phosphatidylcholine
- polysorbates such as Tween 80, Tween 20, or polysorbate 40.
- the EPA, HPA, DPA, or omega-3-pentaenoic acids may be derived from any appropriate source including plant seed oils, microbial oils from algae or fungal or marine oils from fish or other marine animals. Certain species are a particular good source of oils containing DPA, for example seal oil. They may be used in the form of the natural oil, if that oil meets the required purity requirements of the present invention, or may be purified to give products containing the fatty acid composition of the present invention.
- compositions of the present invention may be produced through a range of the methods.
- Such methods may include: distillation, including short path distillation; urea precipitation; enzymatic conversion concentration; conventional chromatography; HPLC/FPLC; supercritical carbondioxide extraction; supercritical carbondioxide chromatography; simulated moving bed chromatography; supercritical carbondioxide simulated moving bed chromatography; or chemical conversion methods such as iodolactonization.
- distillation including short path distillation; urea precipitation; enzymatic conversion concentration; conventional chromatography; HPLC/FPLC; supercritical carbondioxide extraction; supercritical carbondioxide chromatography; simulated moving bed chromatography; supercritical carbondioxide simulated moving bed chromatography; or chemical conversion methods such as iodolactonization.
- Such methods are generally known to those skilled in the art of purifying and isolating omega-3 fatty acids.
- the omega-3 fatty acid concentration/purification process is initiated by esterifying the fatty acids comprised by the marine oil raw material (such as crude fish oil) with ethanol (to form fatty acid ethyl esters) in order to separate omega-3 fatty acids from other fatty acids covalently bound together in the natural triglyceride molecules of the source oil. Subsequently, the material may be distilled once or several times to achieve omega-3-acid ethyl ester concentrations above 60%-70%. Alternatively, enzymatic concentration, urea precipitation or supercritical extraction may be used alone or in conjunction with distillation to reach omega-3 levels above 70%-90%.
- chromatography In order to prepare a highly pure concentrate of a single omega-3 fatty acid, methods such as chromatography, supercritical chromatography, simulated moving bed chromatography, supercritical simulated moving bed chromatography, or chemical conversion methods such as iodolactolization are typically most practical to reach levels above 50%, alternatively above 60%, alternatively above 70%, alternatively above 80%, alternatively above 90%, alternatively above 95%, of a single omega-3 fatty acid such as ETA, EPA, HPA, DPA, TPA, or DHA.
- a single omega-3 fatty acid such as ETA, EPA, HPA, DPA, TPA, or DHA.
- EPA is relatively abundant in fish oils or other marine oils and can be relatively easy obtained through the application of concentration and purification technologies from such fish or marine oils.
- DPA and HPA are present at much lower concentrations.
- DPA or HPA may be concentrated and purified from fish or other marine oils according to the methods referred to above, either alone or DPA combined with EPA and/or HPA.
- the DPA or HPA may be chemically prepared from a high purity EPA concentrate by elongation of the EPA fatty-acid chain with two or one hydrogen- saturated carbons (C2-elongation or C1 -elongation) on the carboxyl side of the molecule (for instance with a method similar to or alternate methods with equivalent results such as described by Kuklev DV and Smith WL in Chem Phys Lipids, 2006; 144(2): 172-177).
- a high purity EPA concentrate may be partially converted to DPA (or HPA) using a method for C2-elongation (or C1 -elongation) of EPA similar to those described above, thus directly yielding compositions of the present invention or intermediates therefore.
- oils containing one or more of the desired fatty acids may be blended to give the desirable relative amounts of EPA, DPA, HPA, DHA, TPA, other omega-3 fatty acids and omega-6 fatty acids to obtain the compositions of the present invention described in detail above.
- Fish oils may also contain by-products and contaminants such as pesticides, chlorinated or brominated hydrocarbons, heavy metals, cholesterol and vitamins. During the production of the concentrate, the concentrations of these components are significantly reduced compared to untreated fish oils. Such reduction is inherent due to the nature of purification methods and their ability to concentrate of several or specific omega-3 fatty acids, thus removing other compounds.
- Triglycerides comprising more than 60% of the omega-3 fatty acids in the composition may be produced from ethyl esters and glycerol by well known, published, or alternative chemical synthetic or enzymatic procedures.
- the free acids may be produced from ethyl esters by well known hydrolization or saponification procedures. Methods for converting ethyl esters to triglycerides, free fatty acids, and other molecular forms comprising fatty acids, are generally known to those skilled in the art chemically or enzymatically converting omega-3 fatty acids from one form to another.
- compositions of the present invention have improved pharmacological features as demonstrated by improved bioavailability in a mammal of EPA, HPA, DPA, DHA, EPA+DHA, EPA+DPA or EPA+HPA+DPA combined, total omega-3-pentaenoic acids, or of total omega-3 fatty acids.
- Key parameters for determining bioavailability are maximum concentration of a therapeutic compound or a metabolite thereof (Cmax); the time from administration to maximum concentration (Tmax); and the area under the concentration curve over time (AUC). Such parameters may be determined under single dose or multiple dose administration regimens. Methods to determine comparative bioavailability in mammals are generally known to those skilled in the art.
- Meal conditions during administration to a subject of omega-3 fatty acid compositions or omega-3 fatty acid formulations can be of special significance for absorption and bioavailability of omega-3 fatty acids.
- the meal conditions typically considered are: fasting (no food at all prior for 8-12 hours prior to administration and 2-3 hours post administration of the treatment); a low fat meat (a meal typically containing less than 25 gram of fat [350-600 Kcal] consumed just before or after the administration of the treatment; typically within a 15-30 minute range); or a high fat meat (a meal containing 40 gram to 75 gram of fat [700-1000 Kcal] consumed just before or after the administration of the treatment; typically within a 15-30 minute range).
- compositions of the present invention are more rapidly absorbed as measured by the time to reach the maximum concentration (Tmax) in blood, serum or plasma of EPA, DPA, DHA , EPA+DPA, EPA+DHA, total omega-3-pentaenoic acids, or total omega-3 fatty acids.
- Tmax under high fat meal administration conditions is less than 8 hours, alternatively less than 6 hours, alternatively approximately 5 hours, alternatively 4 hours or less.
- Tmax under low fat meal administration conditions is less than 8 hours, alternatively less than 6 hours, alternatively approximately 5 hours, alternatively 4 hours or less.
- Tmax under fasting administration conditions is less than 8 hours, alternatively less than 6 hours, alternatively approximately 5 hours, alternatively 4 hours or less.
- Tmax for EPA, DPA, DHA , EPA+DPA, EPA+DHA, or total omega-3 fatty acids are equal or less than than Tmax for AMR101 for EPA, DPA, DHA , EPA+DPA, EPA+DHA, total omega-3- pentaenoic acids, or total omega-3 fatty acids under high fat meat, low fat meal, and fasting administration conditions.
- Tmax for EPA, DPA, DHA , EPA+DPA, EPA+DHA, or total omega-3 fatty acids are less than Tmax for AMR101 for EPA+DHA and to EPA, DPA, DHA , EPA+DPA, EPA+DHA, or total omega-3 fatty acids under either low fat meal, fasting, or both administration conditions.
- the improved bioavailability features described above are apparent upon single dose administration, while in other embodiments the improved bioavailability features described above are apparent after multiple dose administration of formulations according to the present invention as compared to referenced comparator products above or substantial equivalent forms thereof.
- compositions of the present invention are more potent and effective than other omega-3 compositions known in the prior art (such as LOVAZA®, EPANOVATM or VASCEPA®).
- the formulation may be a single daily dose preparation to give in one dose the above intakes, or may be in convenient divided doses, for example, a daily dose formed of two to four soft gelatin or other dosage forms, each containing 300-1500 mg of EPA, EPA+DPA, EPA+DPA+HPA, or omega-3-pentaenoic acids in any form embodied in the present invention.
- Flavourants or emulsifiers may be included, for instance, to make the preparation palatable. Other conventional additives, diluents and excipients may be present.
- the preparation for ingestion may be in the form of a capsule, a dry powder, a tablet, a solution, an oil, an emulsion or any other appropriate form.
- the capsules may be hard or soft gelatin capsules, agar capsules, or any other appropriate capsule.
- the omega-3 fatty acid composition optionally includes chemical antioxidants, such as alpha tocopherol, which are administered in pure form or suspended in a vegetable oil, such as soybean oil or corn oil.
- chemical antioxidants such as alpha tocopherol
- the blended fatty acid compositions may then be incorporated into any appropriate dosage form for oral, enteral, parenteral, rectal, vaginal, dermal or other route of administration.
- Soft or hard gelatin capsules, flavoured oil blends, emulsifiers or other liquid forms, and microencapsulate powders or other dry form vehicles are all appropriate ways of administering the products.
- the formulated final drug product containing the omega-3 fatty acid composition may be administered to a mammal or patient in need thereof in a capsule, a tablet, a powder that can be dispersed in a beverage, or another solid oral dosage form, a liquid, a soft gel capsule or other convenient dosage form such as oral liquid in a capsule, as known in the art.
- the capsule comprises a hard gelatin.
- the combination product may also be contained in a liquid suitable for injection or infusion.
- Example pharmaceutical grade finished dosage forms (a) Soft or hard gelatin capsules each containing 500 mg or 1000 mg of a mix 20 parts of EPA as a free fatty acid to 1 parts of DPA as a free fatty acid; (b) As in (a) but where the EPA and DPA free fatty acids are replaced with the fatty acids in any other appropriate bioassimilable form such as the ethyl esters; (c) As in (a)-(b) but where the material is in the form of a microencapsulated powder which can be used as a powder or compressed into tablets.
- Such powders may be prepared by a variety of technologies known to those skilled in the art; (d) As in (a)-(b) but where the formulation is a liquid or emulsion, appropriately flavoured for palatable oral administration; (e) As in (a)-(b) but where the material is formulated into a pharmaceutically acceptable vehicle appropriate for topical application such as a cream or ointment.
- the omega-3 compositions of the present invention may also be administered with a combination of one or more non-active pharmaceutical ingredients (also known generally herein as "excipients").
- Non-active ingredients serve to solubilize, suspend, thicken, dilute, emulsify, stabilize, preserve, protect, color, flavor, and fashion the active ingredients into an applicable and efficacious preparation that is safe, convenient, and otherwise acceptable for use.
- the non-active ingredients may include colloidal silicon dioxide, crospovidone, lactose monohydrate, lecithin, microcrystalline cellulose, polyvinyl alcohol, povidone, sodium lauryl sulfate, sodium stearyl fumarate, talc, titanium dioxide and xanthum gum.
- pharmaceutically acceptable vehicle includes any of the following: a solution where the first API and optional other ingredients are wholly dissolved in a solubilizer (e.g., a pharmaceutically acceptable solvent or mixture of solvents), wherein the solution remains in clear liquid form at about room temperature; a suspension; an oil; or a semi-solid, wherein the first API and optionally other ingredients are dissolved wholly or partially in a solubilizer (an emulsion, cream, etc.).
- a solubilizer e.g., a pharmaceutically acceptable solvent or mixture of solvents
- a "pharmaceutical grade finished dosage form” as used herein may be construed as a unit dose form suitable for administration to, for example, human or animal subjects, and having content uniformity acceptable to regulatory authorities.
- a pharmaceutical grade finished dosage form should have an amount of API within the range of 85% to 1 15% of the desired dosage and an RSD less than or equal to 6.0%.
- a pharmaceutical grade finished dosage form must be stable (i.e., have a "shelf life") for a pharmaceutically acceptable duration of time, preferably at least six months, alternatively at least one year.or at least two years, when stored at room temperature (about 23 degree Celcius to 27 degree Celcius , preferably about 25 degree Celcius) and 60% relative humidity.
- stability is determined by physical appearance and/or chemical modification of the ingredients, in accordance with standards well- known in the pharmaceutical arts, including those documented in ICH guidelines.
- the omega-3 fatty acid dosage form optionally includes chemical antioxidants, such as alpha tocopherol, oils, such as soybean oil and partially hydrogenated vegetable oil, and lubricants such as fractionated coconut oil, lecithin and a mixture of the same.
- chemical antioxidants such as alpha tocopherol, oils, such as soybean oil and partially hydrogenated vegetable oil
- lubricants such as fractionated coconut oil, lecithin and a mixture of the same.
- compositions of the present invention may be used for the treatment of patients by administering an effective amount of such compositions to a subject in need thereof, such as a subject prone to or afflicted with a disease or condition or in need of treatment for a disease or condition.
- the present invention provides methods of treating, preventing, and reducing the symptoms, pathology or events associated with a disease or condition comprising administration of any of the compositions of the present invention.
- the present invention provides methods of treating, preventing, reducing the occurrence of, and reducing symptoms associated with coronary heart disease (CHD), vascular disease, atherosclerotic disease, or related conditions.
- CHD coronary heart disease
- vascular disease vascular disease
- atherosclerotic disease or related conditions.
- the present invention also provides methods of treating, preventing, reducing the occurrence of, and reducing the symptoms, pathology or events associated with vascular-related diseases or conditions.
- vascular diseases and conditions include, but are not limited to: atherosclerosis, atherosclerosis associated with hypercholesterolemia, hypertriglyceridemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, peripheral artery disease (PAD), heart failure, cardiac arrhythmias, blood coagulatory conditions associated with cardiac arrhythmias, hypertension, coagulation related disorders (including but not limited to post-surgical deep vein thrombosis or other high risk thrombosis conditions), nephropathy and other kidney diseases, renal impairment, retinopathy, cognitive impairment, dementia (including but not limited to ischemic dementia and vascular dementia), and metabolic syndrome.
- compositions of the present invention may be used for the treatment of patients by administering an effective amount of such compositions to a subject or a subject in need thereof, such as a subject prone to or afflicted with a vascular/cardiovascular disease or condition, a subject at risk of vascular/cardiovascular events, or a subject in need of treatment for a vascular/cardiovascular disease or condition.
- the present invention provides for the prevention of death (including all cause mortality, cardiovascular mortality, and cardiac death); the treatment and/or prevention of cardiac events, cardiovascular events and/or vascular events and/or symptoms. In some embodiments, the present invention also provides for the reduction of number or frequency of such events, as well as a reduction or amelioration of symptoms associated with such events.
- Vascular, cardiovascular and/or cardiac events may include, but are not limited to: death due to cardiovascular event (including cardiovascular death and cardiac death), sudden cardiac death, myocardial infarction (fatal or non-fatal), ischemic cardiac attack, ischemic attack, angina, stroke, transient ischemic cerebral attack, thrombosis, deep vein thrombosis, pulmonary embolism, coronary revascularization, coronary revascularization with stent placement, carotid artery revascularization, carotid artery revascularization with stent placement, peripheral artery revascularization, peripheral artery revascularization with stent placement, major coronary event, coronary artery bypass grafting, other blood vessel grafting, treatment of aneurism, plaque rupture, and hospitalization due to cardiovascular event (including angina, acute angina and unstable angina).
- cardiovascular event including angina, acute angina and unstable angina.
- Cardiovascular and/or cardiac events may also include other events deemed to fall in such category by those skilled in the art.
- Study endpoints may comprise individual events or a composite of several of the events described directly above (for the latter the term Major Adverse Cardiovascular Event or MACE is often used).
- the present invention provides methods of retarding the atherosclerotic disease process or improves the vascular healing process in response to presence of atherogenic disease.
- Such retardation or healing may be demonstrated by reduced stenosis and/or restenosis at specific vascular sites over time, reduced or lesser increase in intima-media thickness (IMT) of the arterial wall over time, larger lumen size and/or larger vascular diameter at vascular sites with stenosis or clot built-up over time.
- IMT intima-media thickness
- Such retardation or healing may be determined by intravascular ultrasound (IVUS), radiographic, echocardiographic, radiologic, noninvasive ultrasound, tomography, magnetic resonance interference (MRI), or other acceptable methods.
- IVUS intravascular ultrasound
- MRI magnetic resonance interference
- such retardation or improved healing may be demonstrated by the vascular wall composition, such as a reduced foam cell presence or fibrillated tissue in the vessel wall.
- such improved vascular healing is demonstrated by improved inflammatory markers in the vascular wall or specific types of staining of vascular tissue.
- compositions of the present invention may differentially alter the ratio between blood platelets and fragments thereof (also known as platelet microparticles). Such fragments may be evaluated as a whole or examined and described as fragment sub-categories. [0109] In some embodiments, the compositions of the present invention may differentially alter the surface charge of blood platelets and fragments thereof, either in resting state (non-activated platelets) or activated stage.
- compositions of the present invention may affect the coagulatory cascade and differentially alter coagulation or bleeding times or platelet aggregation times and density.
- compositions of the present invention may be useful for any subjects and they may be especially useful in certain patient populations, including but not limited to the following: subjects having receiving treatment for or in need of treatment for hypertriglyceridemia, hypercholesterolemia, Frederickson dyslipidemia, and other comorbidities.
- the present invention provides for methods of treatment of subjects with no previous cardiovascular events, or subjects with one or more previous cardiovascular events.
- the subjects to be treated with or administered the compositions of the present invention are selected based on their dyslipidemic profile.
- Subjects may be selected for treatment/administration from the following categories: hypertriglyceridemia (such as TG ⁇ 750mg/dL, TG>500mg/dL, TG>200mg/dL, TG>150mg/dL, TG500-2000mg/dL, TG500- 1500mg/dL, TG750-2000mg/dl_, TG750-1500mg/dL, TG200-499mg/dL, TG300- 499mg/dL, TG350-499mg/dl_, TG300-750mg/dl_, TG300-700mg/dL, TG200- 499mg/dL, or TG150-199mg/dL); hypercholesterolemia (such as LDL-C ⁇ 70mg/dL, LDL-C>70mg/dL, LDL-C>100mg/dL, LDL-C>130/dl_, LDL-C>160mg
- the subjects to be treated with or administered the compositions of the present invention are selected based on the presence of certain comorbidities.
- comorbidities may include, but are not limited to the following: renal disease, nephropathy, IgA nephropathy, renal impairment, renal failure (also kidney failure or renal insufficiency), renal insufficiency requiring dialysis, renal insufficiency without dialysis treatment, chronic analgesic nephritis, polycystic kidney disease, proteinuria, hypertension, thrombotic microangiopathy, renal failure (acute renal failure, chronic renal failure), uremic pericarditis, uremia, renal artery stenosis, renal ischemia, hypertensive nephropathy, renovascular hypertension, renal osteodystrophy, nephroptosis, renal cortical necrosis, glomerulitis, metabolic syndrome, diabetes, or pre-diabetes.
- the methods of administering the compositions of the present invention are useful in subjects having cardiopathy, coronary ischemia, cardiac decompensation, or diabetic pathology with cardiopathy, and subjects with previous myocardial infarction, stroke, recent myocardial infarction (post-MI), Acute Coronary Syndrome (ACS), ACS without ST-segment elevation (NSTEMI), ACS with ST-segment elevation (STEMI), or any other major cardiovascular event.
- the compositions of the present invention may reduce the reoccurrence of such cardiovascular events.
- treatment with the compositions of the present invention results in clinical improvement of such comorbidities.
- administration with the compositions of the present invention may reduce the time necessary to achieve clinical improvement and/or attain treatment goals.
- the administration of compositions can result in clinical improvements in clinical markers, including, but not limited to: glomerular filtration rate, serum creatinine, serum urea, serum phosphate levels, serum potassium levels, systolic or diastolic blood pressure, progression to dialysis, progression to renal failure, progression to need for renal transplant, fasting serum glucose levels, postprandial serum glucose levels, serum fructosamine levels, therapeutic insulin utilization, progression to diabetes, hypo-glucose events, hyper- glucose events, or hemoglobin A1 C.
- compositions of the present invention may be co-administered with one or more other therapeutic agents.
- clinical benefits resulting from the administration or treatment of subjects with the compositions of the present invention may be improved with concomitant use or in combination with other therapeutic agents.
- Examples of such concomitant or fixed combination treatments may include coadministration with one or more of the following: an HMG-CoA reductase inhibitor ("statin”), an anti-platelet agent (such as aspirin or clopidogrel), an anti-coagulant (such as warfarin) an antihypertensive (such as a diuretic, beta- blocker, calcium channel blocker, ACE-inhibitor, angiotensin II receptor (ARB) antagonist), or other treatments for cardiovascular diseases.
- an HMG-CoA reductase inhibitor such as aspirin or clopidogrel
- an anti-coagulant such as warfarin
- an antihypertensive such as a diuretic, beta- blocker, calcium channel blocker, ACE-inhibitor, angiotensin II receptor (ARB) antagonist
- the present invention also provides pharmaceutical compositions, for example, a unit dosage, comprising one or more HMG-CoA reductase inhibitors ("statins") and an omega-3 fatty acid composition of the present invention.
- statins HMG-CoA reductase inhibitors
- the present invention provides a fixed dose combination product comprising both a statin and the composition of the present invention.
- the present invention may incorporate currently known or future known statins in an amount generally recognized as safe and effective. There are currently seven statins that are widely available: atorvastatin, rosuvastatin, fluvastatin, lovastatin, pravastatin, pravastatin, and simvastatin. An eighth statin, cerivastatin, has been removed from the U.S. market at the time of this writing.
- cerivastatin may be used in conjunction with some embodiments of the present invention if cerivastatin is ultimately determined to be safe and effective in certain treatment regimens.
- Such statins are typically used at their common daily doses, which include, but are not limited to lovastatin 10mg, 20mg, 40mg; pravastatin 10mg, 20mg, 40mg, 80mg; simvastatin 5mg, 10mg, 20mg, 40mg, 80mg; fluvastatin 20mg, 40mg, 80mg; atorvastatin 10mg, 20mg, 40mg, 80mg; rosuvastatin 5mg, 10mg, 20mg, 40mg; and pitavastatin 1 mg, 2mg, 4mg, 8mg.
- statins are dose dependent, i.e., the higher the dose, the greater the therapeutic affect.
- the effect of each statin is different, and therefore the level of therapeutic effect of one statin cannot be necessarily be directly correlated to the level of therapeutic effects of other statins.
- bioavailability varies widely among the statins. Specifically, it has been shown that simvastatin is less than 5% bioavailable, while fluvastatin is approximately 24% bioavailable. Statins are absorbed at rates ranging from about 30% with lovastatin to 98% with fluvastatin. First-pass metabolism occurs in all statins except pravastatin.
- Pravastatin is also the least protein-bound of the statins (about 50%), compared with the others, which are more than 90% protein-bound. Accordingly, the statins possess distinct properties from one another.
- the combination products of this invention involving each statin or a plurality of statins are also distinct.
- the method of treatment may combine the administration of one or more statins at its common dose or an alternative dose with the composition of the present invention
- a composition according to the present invention is prepared by mixing and homogenizing in a ratio of 98:2 the intermediates MEGAPEX E90D00EE (90% EPA ethyl ester,) and MAXOMEGA DPA95 FFA (>95% DPA synthetic fatty acid produced from EPA ethyl ester concentrate) converted to ethyl ester, respectively.
- MEGAPEX E90D00EE 90% EPA ethyl ester,
- MAXOMEGA DPA95 FFA >95% DPA synthetic fatty acid produced from EPA ethyl ester concentrate
- the resulting novel composition comprises 89.10% EPA, 1.95% DPA, 0.19% HPA, 91.24% omega-3-pentaenoic acids, less than 0.01 % DHA, 91.24% omega-3-pentaenoic acids, 93.09% total omega-3 fatty acids, 3.15% ARA and 3. 57% omega-6 fatty acids (all Area%).
- a composition according to the present prevention is prepared by mixing and homogenizing in a ratio of 96:4 the intermediates MEGAPEX E90D00EE (90% EPA ethyl ester,) and MAXOMEGA DPA95 FFA (>95% DPA synthetic fatty acid produced from EPA ethyl ester concentrate), converted to ethyl ester, respectively.
- MEGAPEX E90D00EE 90% EPA ethyl ester,
- MAXOMEGA DPA95 FFA >95% DPA synthetic fatty acid produced from EPA ethyl ester concentrate
- MAXOMEGA DPA95 FFA
- the resulting novel composition comprises 87.28% EPA, 3.89% DPA, 0.18% HPA, 91.35% omega-3-pentaenoic acids, less than 0.01 % DHA, 93.17% total omega-3 fatty acids and 3.49% omega-6 fatty acids (all Area%).
- a composition according to the present invention is prepared by mixing and homogenizing in a ratio of 94:6 the intermediates MEGAPEX E90D00EE (90% EPA ethyl ester,) and MAXOMEGA DPA95 FFA (>95% DPA synthetic fatty acid produced from EPA ethyl ester concentrate) converted to ethyl ester, respectively.
- MEGAPEX E90D00EE 90% EPA ethyl ester,
- MAXOMEGA DPA95 FFA >95% DPA synthetic fatty acid produced from EPA ethyl ester concentrate
- the resulting novel composition comprises 85.46% EPA, 5.84% DPA, 0.18% HPA, 91.48% omega-3-pentaenoic acids, less than 0.01 % DHA, 93.26% total omega-3 fatty acids, 3.02% ARA, and 3.42% omega- 6 fatty acids (all Area%).
- a composition according to the present invention is prepared by mixing and homogenizing in a ratio of 75:25 the intermediates MEGAPEX E90D00EE (90% EPA ethyl ester,) and MAXOMEGA DPA95 FFA (>95% DPA synthetic fatty acid produced from EPA ethyl ester concentrate, converted to ethyl ester, respectively.
- MEGAPEX E90D00EE 90% EPA ethyl ester,
- MAXOMEGA DPA95 FFA >95% DPA synthetic fatty acid produced from EPA ethyl ester concentrate, converted to ethyl ester, respectively.
- These intermediates were prepared and commercially offered for sale by Chemport Korea (MEGAPEX) and Equateq Ltd from Scotland, UK (MAXOMEGA).
- the relative amounts of fatty acids present in the starting intermediates and in the resulting novel composition is listed in table 4 below.
- the resulting novel composition comprises 68.10% EPA, 24.32% DPA, 0.19% HPA, 92.65% omega-3-pentaenoic acids, less than 0.01 % DHA, 94.07% total omega-3 fatty acids, 2.41 % ARA and 2.73% omega-6 fatty acids (all Area%).
- a composition according to the present invention isprepared by mixing and homogenizing in a ratio of 60:40 the intermediates KD-PharmaKD-PUR 900EE and MAXOMEGA DPA95 FFA converted to ethyl ester, respectively. These intermediates were prepared and commercially offered for sale by KD-Pharma Germany (KD-Pharma) and Equateq Ltd from Scotland, UK (MAXOMEGA). The relative amounts of fatty acids present in the starting intermediates and in the resulting novel composition is listed in table 5 below. The resulting novel composition comprises 55.74% EPA, 39.26% DPA, 2.39% HPA, 97.44% omega-3- pentaenoic acids, and 98.06% total omega-3 fatty acids (all Area%).
- a composition according to the present invention is prepared by mixing and homogenizing in a ratio of 96:4 the intermediates KD-PUR 900EE KD-Pharma and MAXOMEGA DPA95 FFA converted to ethyl ester, respectively. These intermediates were prepared and commercially offered for sale by KD-Pharma Germany (KD-Pharma) and Equateq Ltd from Scotland, UK (MAXOMEGA). The relative amounts of fatty acids present in the starting intermediates and in the resulting novel composition is listed in table 6 below. The resulting novel composition comprises 89.27% EPA, 4.45% DPA, 3.82% HPA, 97.54% omega-3- pentaenoic acids, and 98.54% total omega-3 fatty acids (all Area%).
- a composition according to the present invention is prepared by mixing and homogenizing in a ratio of 91 .8:8.2 the intermediates KD-PUR 910EE KD-Pharma and DPA95 FFA converted to ethyl ester, respectively.
- the relative amounts of fatty acids present in the starting intermediates and in the resulting novel composition is listed in table 7 below.
- the ethyl ester composition of Example 4 may be converted into a free fatty acid composition with essentially the same fatty acid composition according to "Conversion Method EE to FFA" below. This method is indiscriminate with respect to the type, degree of saturation or length of fatty acid if performed for an adequate amount of time under the described conditions.
- Fatty Acid Ethyl Ester (FAEE GMP, approx. 3mmol/g) oil is brought into a closed heated/cooled reaction chamber under nitrogen atmosphere (preferably with pressure control), and heated to 50-60 degree Celcius under stirring.
- Step 4 Repeat Step 4 several times ( ⁇ 2x) to remove ethanol and NaCI.
- Example 3 The ethyl ester composition of Example 3 is converted into a free fatty acid composition with essentially the same fatty acid composition according to "Conversion Method EE to FFA" above. This method is indiscriminate with respect to the type, degree of saturation or length of fatty acid if performed for an adequate amount of time under the described conditions.
- Example 6 The ethyl ester composition of Example 6 is converted into a free fatty acid composition with essentially the same fatty acid composition according to "Conversion Method EE to FFA" above. This method is indiscriminate with respect to the type, degree of saturation or length of fatty acid if performed for an adequate amount of time under the described conditions.
- Example 4 The composition of Example 4 is formulated into a soft gelatin capsule. Prior to encapsulation, an anti-oxidant preparation (composed of 4000 mg alpha-D- tocopherol in one liter of corn oil; corn oil is a triglyceride low in omega-3) is added to the composition of Example 4, by mixing and homogenizing 100ml_ of this antioxidant preparation into 100 liters of the oil composition of Example 4 followed by thorough homogenization. The resulting pre-encapsulation formulated oil contains approximately 4mg/gram alpha-D-tocopherol.
- an anti-oxidant preparation composed of 4000 mg alpha-D- tocopherol in one liter of corn oil; corn oil is a triglyceride low in omega-3
- the resulting pre-encapsulation formulated oil contains approximately 4mg/gram alpha-D-tocopherol.
- the formulated oil is encapsulated into soft gelatin capsules with printed logo according to general methods typically used by Accucaps in Canada for fish oils or by any other documented and operational encapsulation method.
- the fill mass of the oil is approximately 1.08 gram/capsule, providing a dose of approximately 1000mg omega-3-pentaenoic-acids ethyl esters per capsule.
- the capsules are bottled in HDPE bottles with induction seal and child resistant cap.
- Example 9 The composition of Example 9 is formulated into a soft gelatin capsule. Prior to encapsulation, an anti-oxidant preparation (composed of 4000 mg alpha-D- tocopherol in one liter of corn oil; corn oil is a triglyceride low in omega-3) is added to the composition of Example 4, by mixing and homogenizing 100ml_ of this antioxidant preparation into 100 liters of the oil composition of Example 4 followed by thorough homogenization. The resulting pre-encapsulation formulated oil contains approximately 4mg/gram alpha-D-tocopherol.
- an anti-oxidant preparation composed of 4000 mg alpha-D- tocopherol in one liter of corn oil; corn oil is a triglyceride low in omega-3
- the resulting pre-encapsulation formulated oil contains approximately 4mg/gram alpha-D-tocopherol.
- the formulated oil is encapsulated into soft gelatin capsules with printed logo according to general methods typically used by Banner in High Point, NC, for fish oils or by any other documented and operational encapsulation method.
- the fill mass of the oil is approximately 1 .09 gram/capsule, providing a dose of approximately 1000mg omega-3-pentaenoic-acids per capsule.
- the capsules are bottled in HDPE bottles with induction seal and child resistant cap.
- Example 5 The composition of Example 5 is formulated into a soft gelatin capsule. Prior to encapsulation, an anti-oxidant preparation (composed of 4000 mg alpha-D- tocopherol in one liter of corn oil; corn oil is a triglyceride low in omega-3) is added to the composition of Example 4, by mixing and homogenizing 100mL of this antioxidant preparation into 100 liters of the oil composition of Example 4 followed by thorough homogenization.
- the resulting pre-encapsulation formulated oil contains approximately 4mg/gram alpha-D-tocopherol.
- the formulated oil is encapsulated into soft gelatin capsules with printed logo according to general methods typically used by Catalent in St.Petersburg, FL, for fish oils or by any other documented and operational encapsulation method.
- the fill mass of the oil is approximately 1 .05 gram/capsule, providing a dose of approximately 1000mg omega-3-pentaenoic-acids ethyl esters per capsule.
- the capsules are bottled in HDPE bottles with induction seal and child resistant cap.
- Example 14 The composition of Example 10 is formulated into a soft gelatin capsule. Prior to encapsulation, an anti-oxidant preparation (composed of 4000 mg alpha-D- tocopherol in one liter of corn oil; corn oil is a triglyceride low in omega-3) is added to the composition of Example 4, by mixing and homogenizing 100ml_ of this antioxidant preparation into 100 liters of the oil composition of Example 4 followed by thorough homogenization. The resulting pre-encapsulation formulated oil contains approximately 4mg/gram alpha-D-tocopherol.
- an anti-oxidant preparation composed of 4000 mg alpha-D- tocopherol in one liter of corn oil; corn oil is a triglyceride low in omega-3
- the resulting pre-encapsulation formulated oil contains approximately 4mg/gram alpha-D-tocopherol.
- the formulated oil is encapsulated into soft gelatin capsules with printed logo according to general methods typically used by Banner in High Point, NC, for fish oils or by any other documented and operational encapsulation method.
- the fill mass of the oil is 1 .06 gram/capsule, providing a dose of approximately 1000mg omega-3-pentaenoic-acids per capsule.
- the capsules are bottled in HDPE bottles with induction seal and child resistant cap.
- a patient is diagnosed with vascular disease. Thereupon, the patient may be initiated on daily treatment with one of the encapsulated compositions according to Examples 10, 1 1 , 12 or 13. Four capsules per day are administered to this patient (4g/d).
- a patient is treated as per Example 15. The treatment results in significant reduction of the occurrence of MACE.
- DPA Docosapentaenoic acid 60 100 80
- DHA Docosahexaenoic acid
- DPA Docosapentaenoic acid
- EPA:DPA ratio is between 8 and 15, the HPA: DPA ration between 0.05 and 1 , the DPA:DHA ratio more than 2.4, preferably more than 4, more preferably more than 6, most preferably more than 10, and the EPA:DHA ratio more than 32, preferably more than 38, more preferably more than 80, most preferably more than 95.
- the EPA, HPA, DPA and DHA may be composed as a glyceride (such as triglyceride), an ester (such as ethyl ester), or a free fatty acid.
- the EPA:HPA ratio is between 0.25 and 12
- the DPA:EPA ratio is between 13 and 63
- the DPA:HPA ration between 13 and 190
- the EPA:DHA ratio more than 00.6, preferably more than 1.5, more preferably more than 2.4, most preferably more than 6.
- the EPA, HPA, DPA and DHA may be composed as a glyceride (such as triglyceride), an ester (such as ethyl ester), or a free fatty acid.
- the DPA may be composed as a glyceride (such as triglyceride), an ester (such as ethyl ester), or a free fatty acid.
- a mixture of DPA and EPA was prepared by combining 1 g DPA Ethyl Ester (SE-133-III) with 10g EPA Ethyl Ester, 914 mg/g (KD Pharma FM13001 ) in 150ml of 95% ethanol/water containing 35ml of 2M sodium hydroxide. This reaction mixture was stirred overnight at ambient temperature. Tic analysis showed complete conversion of the ethyl esters to the corresponding acids. The reaction mixture was cooled in an ice bath, acidified with 6N hydrochloric acid and concentrated on a rotavap under reduced pressure. Water and ethyl acetate were added, the phases separated and the aqueous residue extracted with ethyl acetate.
- a fatty acid composition comprising at least 50% omega-3-fatty acids, salts or derivatives thereof, while comprising eicosapentaenoic acid (EPA; C20:5-n3) and docosapentaenoic acid (DPA; C22:5-n3) and wherein the EPA:DHA ratio is higher than 20:1 .
- EPA eicosapentaenoic acid
- DPA docosapentaenoic acid
- a fatty acid composition comprising at least 60% omega-3-fatty acids, salts or derivatives thereof, while comprising eicosapentaenoic acid (EPA; C20:5-n3) and docosapentaenoic acid (DPA; C22:5-n3) and wherein the EPA:DHA ratio is higher than 20:1.
- EPA eicosapentaenoic acid
- DPA docosapentaenoic acid
- a fatty acid composition comprising at least 70% omega-3-fatty acids, salts or derivatives thereof, while comprising eicosapentaenoic acid (EPA; C20:5-n3) and docosapentaenoic acid (DPA; C22:5-n3) and wherein the EPA:DHA ratio is higher than 20:1 .
- EPA eicosapentaenoic acid
- DPA docosapentaenoic acid
- a fatty acid composition comprising at least 75% omega-3-fatty acids, salts or derivatives thereof, while comprising eicosapentaenoic acid (EPA; C20:5-n3) and docosapentaenoic acid (DPA; C22:5-n3) and wherein the EPA:DHA ratio is higher than 20:1 .
- EPA eicosapentaenoic acid
- DPA docosapentaenoic acid
- a fatty acid composition comprising at least 80% omega-3-fatty acids, salts or derivatives thereof, while comprising eicosapentaenoic acid (EPA; C20:5-n3) and docosapentaenoic acid (DPA; C22:5-n3) and wherein the EPA:DHA ratio is higher than 20:1 .
- EPA eicosapentaenoic acid
- DPA docosapentaenoic acid
- a fatty acid composition comprising at least 85% omega-3-fatty acids, salts or derivatives thereof, while comprising eicosapentaenoic acid (EPA; C20:5-n3) and docosapentaenoic acid (DPA; C22:5-n3) and wherein the EPA:DHA ratio is higher than 20:1.
- EPA eicosapentaenoic acid
- DPA docosapentaenoic acid
- a fatty acid composition comprising at least 90% omega-3-fatty acids, salts or derivatives thereof, while comprising eicosapentaenoic acid (EPA; C20:5-n3) and docosapentaenoic acid (DPA; C22:5-n3) and wherein the EPA:DHA ratio is higher than 20:1 .
- EPA eicosapentaenoic acid
- DPA docosapentaenoic acid
- a fatty acid composition comprising at least 95% omega-3-fatty acids, salts or derivatives thereof, while comprising eicosapentaenoic acid (EPA; C20:5-n3) and docosapentaenoic acid (DPA; C22:5-n3) and wherein the EPA:DHA ratio is higher than 20:1 .
- EPA eicosapentaenoic acid
- DPA docosapentaenoic acid
- composition according to one of the preferred embodiments 1 through 8 comprising at least 2% docosapentaenoic acid (DPA; C22:5-n3).
- DPA docosapentaenoic acid
- DPA docosapentaenoic acid
- composition according to one of the preferred embodiments 1 through 8 comprising at least 5% docosapentaenoic acid (DPA; C22:5-n3).
- DPA docosapentaenoic acid
- DPA docosapentaenoic acid
- composition according to one of the preferred embodiments 1 through 8 comprising at least 7% docosapentaenoic acid (DPA; C22:5-n3).
- DPA docosapentaenoic acid
- composition according to one of the preferred embodiments 1 through 8 comprising at least 8% docosapentaenoic acid (DPA; C22:5-n3).
- DPA docosapentaenoic acid
- DPA docosapentaenoic acid
- composition according to one of the preferred embodiments 1 through 8 comprising at least 12% docosapentaenoic acid (DPA; C22:5-n3).
- composition according to one of the preferred embodiments 1 through 8 comprising at least 15% docosapentaenoic acid (DPA; C22:5-n3).
- DPA docosapentaenoic acid
- composition according to one of the preferred embodiments 1 through 17, comprising no more than 95% EPA.
- composition according to one of the preferred embodiments 1 through 22, comprising no more than 3% arachidonic acid (C22:4-n6).
- composition according to one of the preferred embodiments 1 through 22, comprising no more than 2% arachidonic acid (C22:4-n6).
- composition according to one of the preferred embodiments 1 through 22, comprising no more than 1 % arachidonic acid (C22:4-n6).
- composition according to one of the preferred embodiments 1 through 27, comprising at least 0.01 % heneicosapentaenoic acid (C21 :5-n3).
- composition according to one of the preferred embodiments 1 through 27, comprising at least 0.3% heneicosapentaenoic acid (C21 :5-n3).
- composition according to one of the preferred embodiments 1 through 27, comprising at least 0.5% heneicosapentaenoic acid (C21 :5-n3).
- composition according to one of the preferred embodiments 1 through 27, comprising at least 1 % heneicosapentaenoic acid (C21 :5-n3).
- composition according to one of the preferred embodiments 1 through 27, comprising at least 2% heneicosapentaenoic acid (C21 :5-n3).
- composition according to one of the preferred embodiments 1 through 27, comprising at least 3% heneicosapentaenoic acid (C21 :5-n3).
- composition according to one of the preferred embodiments 1 through 27, comprising at least 4% heneicosapentaenoic acid (C21 :5-n3).
- composition according to one of the preferred embodiments 1 through 27, comprising at least 5% heneicosapentaenoic acid (C21 :5-n3).
- a composition according to one of the preferred embodiments 1 through 37 comprising no more than 5% omega-3 fatty acids that are not omega-3- pentaenoic acids.
- a composition according to one of the preferred embodiments 1 through 37 comprising no more than 4% omega-3 fatty acids that are not omega-3- pentaenoic acids.
- a composition according to one of the preferred embodiments 1 through 37 comprising no more than 3% omega-3 fatty acids that are not omega-3- pentaenoic acids.
- a composition according to one of the preferred embodiments 1 through 37 comprising no more than 2% omega-3 fatty acids that are not omega-3- pentaenoic acids.
- a composition according to one of the preferred embodiments 1 through 37 comprising no more than 1.5% omega-3 fatty acids that are not omega-3- pentaenoic acids.
- a composition according to one of the preferred embodiments 1 through 37 comprising no more than 1.25% omega-3 fatty acids that are not omega-3- pentaenoic acids.
- a composition according to one of the preferred embodiments 1 through 37 comprising no more than 1 % omega-3 fatty acids that are not omega-3- pentaenoic acids.
- composition according to one of the preferred embodiments through 44 wherein the EPA:DPA ratio is between 5:1 and 1 :1.
- composition according to one of the preferred embodiments 1 through 44 comprising between 65% and 95% EPA.
- composition according to one of the preferred embodiments 1 through 44 comprising between 75% and 95% EPA.
- a composition according to one of the preferred embodiments 1 through 44 comprising between 80% and 95% EPA.
- a composition according to one of the preferred embodiments 1 through 44 comprising between 85% and 95% EPA.
- composition according to one of the preferred embodiments 1 through 44 comprising between 90% and 95% EPA.
- composition according to one of the preferred embodiments 1 through 44 comprising between 2% and 10% DPA.
- composition according to one of the preferred embodiments 1 through 44 comprising between 3% and 20% DPA.
- composition according to one of the preferred embodiments 1 through 44 comprising between 3% and 30% DPA.
- composition according to one of the preferred embodiments 1 through 44 comprising between 3% and 50% DPA.
- composition according to one of the preferred embodiments 1 through 44 comprising between 3% and 75% DPA.
- composition according to one of the preferred embodiments 1 through 44 comprising between 3% and 90% DPA.
- a fatty acid composition according to one of the preferred embodiments 94 through 97 also comprising a suitable anti-oxidant in a concentration sufficient to protect the fatty acids of the composition from oxidation.
- a pharmaceutically suitable formulation comprising one of the compositions according to preferred embodiments 94 through 98, in which the amount of eicosapentaenoic acid plus docosapentaenoic acid is present in an amount between 100 and 10,000 mg.
- a pharmaceutically suitable formulation or dosage form comprising one of the compositions according to preferred embodiments 94 through 98, in which the amount of eicosapentaenoic acid plus docosapentaenoic acid is present in an amount between 250 and 1 ,250 mg.
- a pharmaceutically suitable formulation or dosage form comprising one of the compositions according to preferred embodiments 94 through 98, in which the amount of eicosapentaenoic acid plus docosapentaenoic acid is present in an amount between 500 and 1 ,100 mg.
- a pharmaceutically suitable formulation or dosage form comprising one of the compositions according to preferred embodiments 94 through 98, in which the amount of eicosapentaenoic acid plus docosapentaenoic acid is present in an amount between 100 and 10,000 mg.
- a method of treatment according to preferred embodiments 03 through 105 in which the subject is a patient diagnosed with high triglycerides (equal to or more than 200 mg/dL but less than 500 mg/dL).
- 108. A method of treatment according to preferred embodiments 103 through 105, in which the subject is a patient already undergoing treatment with a statin and then diagnosed with high triglycerides (equal to or more than 200 mg/dL but less than 500 mg/dL).
- a method of treatment according to preferred embodiments 103 through 105 in which the subject is a patient diagnosed with mixed dyslipidemia with TG 200- 499 mg/dL and LDL-cholesterol equal to or more than 130 mg/dL.
- a method of treatment according to preferred embodiments 103 through 105 in which the subject is a patient diagnosed with mixed dyslipidemia with TG 300- 700 mg/dL and LDL-cholesterol equal to or more than 130 mg/dL.
- the composition of claim 1 wherein the ratio of EPA to DPA (EPA:DPA) is between 15:1 to 8:1.
- An orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-pentaenoic acids, salts, esters, or derivatives thereof, wherein the composition comprises eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA), and wherein the ratio of DHA to EPA (DHA:EPA) is less than 1 :20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 .
- EPA eicosapentaenoic acid
- DPA docosapentaenoic acid
- DHA docosahexaenoic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Edible Oils And Fats (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361780948P | 2013-03-13 | 2013-03-13 | |
PCT/US2013/075661 WO2014143272A1 (en) | 2013-03-13 | 2013-12-17 | Omega-3 pentaenoic acid compositions and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2968246A1 true EP2968246A1 (en) | 2016-01-20 |
EP2968246A4 EP2968246A4 (en) | 2016-08-03 |
Family
ID=51537458
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13878433.5A Withdrawn EP2968246A4 (en) | 2013-03-13 | 2013-12-17 | Omega-3 pentaenoic acid compositions and methods of use |
EP14779339.2A Withdrawn EP2986148A2 (en) | 2013-03-13 | 2014-03-12 | Compositions comprising docosapentaenoic acid and methods of use |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14779339.2A Withdrawn EP2986148A2 (en) | 2013-03-13 | 2014-03-12 | Compositions comprising docosapentaenoic acid and methods of use |
Country Status (4)
Country | Link |
---|---|
EP (2) | EP2968246A4 (en) |
JP (2) | JP2016518315A (en) |
CA (2) | CA2905671A1 (en) |
WO (4) | WO2014158256A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2934132T3 (en) | 2014-12-15 | 2023-02-17 | Dsm Ip Assets Bv | Treatment for non-alcoholic fatty liver disease |
CN106692973A (en) * | 2015-11-13 | 2017-05-24 | 深圳君圣泰生物技术有限公司 | Pharmaceutical compositions and applications thereof, and pharmaceutical preparation |
EP3456328A4 (en) * | 2016-05-10 | 2020-02-26 | Shenzhen Hightide Biopharmaceutical., Ltd. | Composition, and application and pharmaceutical preparation thereof |
JP2020508285A (en) * | 2017-02-09 | 2020-03-19 | エス.エル.アー. ファーマ アーゲー | High-purity eicosapentaenoic acid as a free fatty acid reduces stool calprotectin levels in patients with ulcerative colitis and prevents clinical recurrence |
CN107006809B (en) * | 2017-04-11 | 2020-06-09 | 江南大学 | Vinegar onion product with blood fat reducing effect and preparation method thereof |
JP7099821B2 (en) * | 2017-12-20 | 2022-07-12 | ポッカサッポロフード&ビバレッジ株式会社 | PCSK9 inhibitor and food composition for improving cholesterol metabolism |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070104856A1 (en) * | 2003-05-05 | 2007-05-10 | Hakon Standal | Fish oils with an altered fatty acid profile, method of producing same and their use |
EP1656839A1 (en) * | 2004-11-11 | 2006-05-17 | N.V. Nutricia | Nutrition containing lipid blend |
EP1824809A4 (en) * | 2004-11-19 | 2010-03-03 | Martek Biosciences Corp | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same |
EP1714564A1 (en) * | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Method for treatment and prevention of respiratory insufficiency |
WO2007058523A1 (en) * | 2005-11-17 | 2007-05-24 | N.V. Nutricia | Composition with docosapentaenoic acid |
KR100684642B1 (en) * | 2006-09-14 | 2007-02-22 | 주식회사 일신웰스 | Glyceride oil composition from fish oil and preparation method thereof |
LT3037089T (en) * | 2009-02-10 | 2020-01-10 | Amarin Pharmaceuticals Ireland Limited | Eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia |
KR101841756B1 (en) * | 2009-03-09 | 2018-03-23 | 프로노바 바이오파마 너지 에이에스 | Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof |
US20110071090A1 (en) * | 2009-03-11 | 2011-03-24 | Stable Solutions Llc | Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle |
CN106822080A (en) * | 2009-04-29 | 2017-06-13 | 阿马里纳药物爱尔兰有限公司 | Pharmaceutical composition containing EPA and cardiovascular agents and use its method |
US20110177061A1 (en) * | 2009-07-10 | 2011-07-21 | Martek Biosciences Corporation | Methods of treating and preventing neurological disorders using docosahexaenoic acid |
CA2989078C (en) * | 2009-10-29 | 2020-06-30 | Acasti Pharma, Inc. | Concentrated therapeutic phosholipid compositions |
US20120302639A1 (en) * | 2011-02-16 | 2012-11-29 | Pivotal Therapeutics Inc. | Omega 3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death |
WO2013033618A1 (en) * | 2011-09-02 | 2013-03-07 | Arctic Nutrition As | Lipid compositions with high dha content |
AU2013277441B2 (en) * | 2012-06-17 | 2017-07-06 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
-
2013
- 2013-12-17 WO PCT/US2013/075704 patent/WO2014158256A1/en active Application Filing
- 2013-12-17 EP EP13878433.5A patent/EP2968246A4/en not_active Withdrawn
- 2013-12-17 WO PCT/US2013/075740 patent/WO2014143275A1/en active Application Filing
- 2013-12-17 WO PCT/US2013/075661 patent/WO2014143272A1/en active Application Filing
- 2013-12-17 CA CA2905671A patent/CA2905671A1/en not_active Abandoned
- 2013-12-17 JP JP2016500125A patent/JP2016518315A/en active Pending
-
2014
- 2014-03-12 EP EP14779339.2A patent/EP2986148A2/en not_active Withdrawn
- 2014-03-12 CA CA2905795A patent/CA2905795A1/en not_active Abandoned
- 2014-03-12 WO PCT/US2014/024712 patent/WO2014165190A2/en active Application Filing
- 2014-03-12 JP JP2016501615A patent/JP2016512544A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2016512544A (en) | 2016-04-28 |
CA2905671A1 (en) | 2014-09-18 |
JP2016518315A (en) | 2016-06-23 |
CA2905795A1 (en) | 2014-10-09 |
WO2014143272A1 (en) | 2014-09-18 |
EP2986148A2 (en) | 2016-02-24 |
EP2968246A4 (en) | 2016-08-03 |
WO2014165190A3 (en) | 2015-01-29 |
WO2014143275A1 (en) | 2014-09-18 |
WO2014165190A2 (en) | 2014-10-09 |
WO2014158256A1 (en) | 2014-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210205254A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
WO2014179325A1 (en) | Omega-3 fatty acid formulations for use as pharmaceutical treatment | |
AU2020203658A1 (en) | Administering compositions comprising docosapentaenoic acid | |
EP2968246A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
WO2014179341A1 (en) | Treatment with omega-3 fatty acid compositions | |
US20140194512A1 (en) | Compositions comprising docosapentaenoic acid and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150930 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20160704 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/232 20060101ALI20160628BHEP Ipc: A61K 31/202 20060101AFI20160628BHEP Ipc: A61K 9/48 20060101ALI20160628BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20170201 |